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THE MILL, THE STONE, AND THE WATER 
 
All our desire is a grain of wheat. 
Our whole personality is the milling-building. 
But this mill grinds without knowing about it. 
 
The millstone is your heavy body. 
What makes the stone turn is your thought-river. 
The stone says: I don’t know why we do all this, 
  but the river has knowledge! 
 
If you ask the river, it says,  
I don’t know why I flow,  
All I know is that a human opended the gate! 
 
And if you ask the person, he says: 
All I know, oh gobble of bread, is that if this 
 stone stops going around, there’ll be no bread for your bread-soup! 
All this grinding goes on, and no one has any 
 knowledge! 
So just be quiet, and one day turn to God, and say: 
” What is this about bread-making?”   
 
 
Hz. Mevlana Celaleddin Rumi 
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ABSTRACT 
 
Human papillomaviruses have been identified as the major aetiological factor in cervical 
carcinogenesis. Constitutive expression of the high-risk HPV E6 and E7 oncoproteins are important for 
the malignant transformation during the course of infection. In particular, E6 binds to p53 and E7 binds 
to pRb to mediate their proteasomal degradation which is a crucial step for the HPV procured cell cycle 
progression. In order to analyse the biological outcomes in context of the HPV transformed cells, anti-
tumour agents known as HDAC inhibitors (HDACi) were used.  
In the work presented here, the interest was precisely focused to analyse the role of E7 in tumour 
suppressor protein pRb degradation following HDAC inhibition. Initial observation in HPV18 positive 
cervical carcinoma cells HeLa and SW756, demonstrated an E7 dependent degradation of pRb upon SB 
and TSA. This observation was confirmed further by using the HPV negative cervical cancer cells C33-
A and HT-3. Furthermore, to prove whether tumorigenic phenotype was a critical determinant, the 
effect of HDACi on the Stanbridge cell system (non-tumorigenic 444 and the tumorigenic CGL-3 cells) 
was analysed. No discernible difference in pRb degradation was observed between the different cell 
segregates. Moreover the use of the individual E6 and E7 immortalised keratinocytes significantly 
demonstrate the functional link between E7 and pRb degradation.  
The pRb protein is able to repress the transcription of the cell cycle regulatory proteins (cyclin E, DNA 
polymerase-α, dihydrofolate reductase (DHFR) etc.), involved in the G1 to S phase by binding the 
transcription factor E2F and recruiting the HDAC1 molecules to their promoters. To investigate 
whether pRb degradation was accompanied with the upregulation of the key molecules involved in G1 
to S transition the protein level of cyclin E was examined. Western Blot analysis was performed in 
HeLa, 444, CGL3 cells and in E6- and E7- immortalised keratinocytes. Essentially, cyclin E 
upregulation was observed while the E2F protein level was unchanged in HPV 18 containing cells and 
in E7 immortalised keratinocytes. These results demonstrate that the presence of E7 oncoprotein is a 
prerequisite for pRb degradation upon HDAC inhibition. In order to establish more functional link 
between E7 and pRb degradation upon HDAC inhibition, two experimental approaches were used. At 
first, the E7 oncoprotein was knocked down by using siRNA in the HeLa cells. Secondly, E7 
oncoprotein was introduced in TE-671 which are HPV negative, but pRb positive cells. In both 
systems, we observed that E7 has an indispensable role on pRb degradation upon HDACi treatment.  
In order to dissect the role of the individual oncoprotein in HDACi induced pRb degradation, E6 and 
E7 immortalised keratinocytes were used. Treatment of the cells with proteasome-inhibitor MG132 (2 
µM, 16 h) shows that the degradation of pRb occurs via 26S proteasome pathway in E7 immortalised 
keratinocytes. 
In order to accentuate the importance of the direct interaction between E7 and pRb, a serine protease 
inhibitor TLCK was used. In particular, modification of the E7 protein by using the TLCK, rescued 
pRb from HDACi induced degradation. Furthermore, cyclin E which is negatively regulated by pRb 
was downregulated again. These results emphasized the importance of the physical association between 
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E7 and pRb and the crucial role of the LXCXE motif of E7 protein. In addition, co-treatment of SB 
with TLCK interferes with the SB mediated G1 arrest, which was shown by the cell cycle distribution 
analysis and downregulation of the cyclin-dependent kinase inibitor p21. Furthermore, p21 is activated 
in response of HDACi which is responsible for the inactivation of the cyclin/CDK complexes in G1 
phase.  
In order to analyse the HDACi induced apoptosis in the context of HPV, Hela cells were treated with 
SB and TSA and apoptotic cells were analysed by flow cytometry. Consistently, HeLa cells expressed 
apoptotic markers within at 24 hours while the HPV negative cervical cancer cells C33-A were not 
sensitive for apoptosis in response to HDACi treatment. Furthermore this confirmed the crucial role of 
the E7-pRb interaction for the HDACi mediated apoptosis. HDACi induced cell death mainly by 
activating the intrinsic apoptotic pathway. In order to address the target apoptotic gene expression in 
the HPV context and individual oncogenes, Hela cells and the E6- and E7-immortalised keratinocytes 
were used. After treatment with SB, RT-PCR (real-time) analyses were performed for p73 expression. 
The E2F mediated apoptotic protein p73 was upregulated in response to HDACi treatment. This effect 
was reversed by TLCK treatment in HeLa as well as in E7 immortalised keratinocytes. Thus p73 
transcription was reduced in HeLa cells as well as in E7 immortalised keratinocytes. These data 
confirm the presence of HPV E7, which sensitizes the cells for SB mediated apoptosis, and which can 
be reversible by posttranslational modification of the HPV E7. Finally the HDAC inhibitor mediated 
apoptosis can be inhibited by TLCK. Subsequently this study bears new future aspects in understanding 
the role of serine proteases during HDAC inhibition. 
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ZUSAMMENFASSUNG 
 
In der Ätiologie der Zervixkarzinome spielt die Infektion mit „high-risk“ Typen humaner Papillomviren 
eine entscheidende Rolle (zur Hausen, 1996). Die konstitutive Expression der viralen Onkogene E6 und 
E7 und deren Interaktionen mit Regulatoren des Zellzyklus sind wichtig bei der malignen Transformation 
der Wirtszellen. Insbesondere die proteasomale Degradation des Tumorsuppressorproteins p53 durch E6 
und die Degradation von pRb durch Interaktion mit E7, zeichnen sich als eine wichtige Stufe im Rahmen 
der HPV vermittelten Deregulation des Zellzykluses dar. Diese Gruppe von antitumor Agenzien zeichnen 
sich durch potenziellen Inhibierung der Zellzyklus- Progression, Differenzierung und/oder von Apoptose 
in Tumorzellen aus, während normale humane Zellen eher moderat beeinflusst werden.  
In der vorliegenden Arbeit wurde im besonderem die Rolle von HPV E7 bei der HDAC inhibitoren 
induzierten Degradation des Tumorsuppressor Proteins pRb untersucht. Die ersten Ergebnisse mit den 
HPV18 positiven HeLa und SW756 Zellen zeigten, dass  die Präsenz von HPVE7 eine Rolle bei der 
HDAC-Inhibitoren induzierten pRb Degradation spielt. In weiteren Untersuchungen zeigten  die HPV 
negativen Zervixkarzinom Zellen C33-A und HT-3 keine pRb Degradation. Des weiterem wurde 
festgestellt, dass der tumorigene Phänotype keine Rolle in diesem Kontext spielt, indem das Stanbridge 
System verwendet wurde, welches aus der Fusion von HeLa und humanem Fibroblasten, den 444 und 
deren tumorgene Subklonen CGL-3 besteht. Im besonderen zeigte die Behandlung von Keratinozyten, 
welche individuell mit E6 und mit E7 Onkogenen transfiziert worden sind, dass nur in E7 
immortalisierten Keratinozyten eine pRb Degradation Zustande kam, während in E6 Keratinozyten nur  
hypophosphoryliertes pRb zu beobachten war. Das pRb ist unter anderem auch zuständig für die 
transkriptionelle Regulation der regulatorischen Proteine der G1 Phase durch direkte Bindung an den E2F 
Transkriptionsfaktor. Im Rahmen der HDACi Behandlung war es daher wichtig zu untersuchen, ob die 
von pRb negativ regulierten Proteine wie Cyclin E hochreguliert werden konnten, wenn pRb degradiert 
war. Western blot Analysen zeigten, dass dies in HPV 18 positiven und E7 immortalisierten 
Keratinozyten der Fall war, während die Proteinmenge von E2F unverändert blieb. Dies bestätigte des 
weiteren, dass die E7 Präsenz eine Vorraussetzung für die HDAC inhibitoren vermittelte pRb 
Degradation ist. Weiterhin wurde durch Behandlung mit dem Proteasom-Inhibitor MG132 bewiesen, dass 
die Degradation von pRb bei der HDACi- Behandlung zum größten Teil über das 26S Proteasom System 
durchgeführt wird und das E7- Protein in diesem Zusammenhang eine direkte Funktion übernimmt. Um 
unsere Hypothese zu bekräftigen, wurden zwei Ansätze verfolgt. Zuerst wurden  HeLa Zellen mit einer 
siRNA die gegen HPV18E7 gerichtet ist transfiziert. Obwohl dadurch keine bemerkenswerte 
Hochregulierung von pRb beobachtet wurde, konnte man feststellen dass eine hypophosphorylierte pRb 
Bande nach SB Behandlung entstand. Als nächstes wurde in  HPV negativen aber pRb positiven 
Rhabdomyosarcoma Zellen (TE-671), HPV E7 eingeführt. Die Behandlung mit SB  zeigte dass nach 
Einführen des E7 Onkoproteins eine gesteigerte Degradation von pRb zu beobachten war.    
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Um zu beweisen dass die direkte Interaktion zwischen E7 und pRb eine entscheidende Rolle für die 
beobachtete HDACi vermittelte Degradation ist, wurden HeLa Zellen zusammen mit dem Serineprotease 
Inhibitor (TLCK) mit SB behandelt. Die Ergebnisse zeigten, dass TLCK die SB vermittelte Degradation 
zum größten Teil aufheben konnte und das von pRb negativ regulierte Cyclin E abnahm. Zudem konnte 
auch gezeigt werden, dass TLCK mit dem von SB verursachten G1 Arrest interferieren kann, der ab 16 
Stunden Behandlung zustande kam. Diese Beobachtung konnte durch Western Blot Analyse von p21 
bestätigt werden, die eine Abnahme von p21 unter TLCK Behandlung zeigten. Der HDACi vermittelte 
G1 Arrest wird im wesentlichen dadurch verursacht, dass p21 auf der transkriptionellen Ebene aktiviert 
wird. Längere Behandlungen mit HDACi, beginnend ab 24 Stunden zeigten einen apoptotischen 
Phänotyp in HeLa Zellen, während die HPV negativen Zervixkarzinom Zellen C33-A sich nicht 
apoptotisch verhielten. Das bekräftigte die Voraussage, dass die Präsenz von HPV die Zellen zu HDACi 
induzierter Apoptose begünstigen. Insbesondere hebt dieses die wichtige Interaktion zwischen pRb und 
E7 hervor. Die von HDAC Inhibitoren verursachte Apoptose wird in den meisten Fällen durch den 
mitochondrialen Weg  vermittelt. Um auf der molekularen Ebene  festzustellen welche Gene die diesen 
Mechanismus einleiten können, auf Grund der aufgehobenen pRb Repression aktiviert werden, wurde die 
transkriptionelle Untersuchung des proapoptotischen proteins p73 nach Behandlung mit HDACi 
analysiert. Hierfür wurden HeLa und die mit den Onkogenen E6 und E7 immortalisierten Keratinozyten 
eingesetzt. Die Ergebnisse zeigten, dass p73  in HeLa und in E7 Keratinozyten induziert wurde, während 
in E6 Keratinozyten eine moderate Hochregulierung zu sehen war. Interessanterweise wurde diese 
Transkription nach der  Inkubation zusammnen mit TLCK reduziert. Diese Daten belegen, dass E7 die 
HPV positiven Zellen für HDAC Inhibitor vermittelte Apoptose sensibilisieren kann, welches durch 
posttranslationale Modifikation von E7 aufgehoben wird. Darüber hinaus zeigen diese Ergebnisse dass 
die Serinproteasen eine wichtige Rolle bei HDAC Inhibitor vermittelten Effekten haben können.      
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I.    INTRODUCTION 
 
1.1 Human papillomavirus (HPV) infection can cause benign and malignant tumors on 
squamous epithelial cells  
 
Human papillomviruses (HPVs) are small DNA tumor viruses that cause benign and malignant 
tumors of squamous epithelia. So far more than 100 HPV subtypes have been identified and all 
of them appear to be strictly epitheliotropic: They infect epithelial cells of the skin or of the 
anogenital and oropharyngeal mucosa (Aguilar-Lemarroy et al. 2002) zur Hausen, 1999 and 
1996).  
Approximately 40 HPV types that infect the genital tract fall into two discrete groups:  
-Low-risk, non-oncogenic HPV types 6 and 11 and their relatives causes anogenital warts 
(condylomata accuminata) and are rarely detected in malignant disease (Boshart and zur Hausen 
1986;  zur Hausen,  2000). 
-High-risk, oncogenic HPV (hrHPV) types 16, 18, 31, 33, 35, 45, 52, 56 plus about eight other 
minor types (zur Hausen, 2000 and 2002). 
These can be detected in almost 100% of cervical cancer biopsies and more than 90% of the 
high-grade, cervical intra-epithelial neoplasia (CIN2/3) precursor lesions. HPV 16 is the most 
frequent detected HPV in cervical cancers (about 50–60%) with HPV 18 (10–12%) being the 
second most common (Stanley et al., 2004). 
 
1.2 Cervical cancer is causally linked with HPV infection  
 
Carcinomas of the anogenital tract, particularly cancer of the cervix, account for almost 12 % of 
all cancers in woman and represent the second most common gynaecological malignancy in the 
world. Almost all squamous cell carcinomas and a vast majority of adenocarcinomas of the 
cervix are HPV positive (Tjalma et al., 2005; zur Hausen 2002; Bosch et al., 2003a and 2003b).  
The development of cervical cancer has been linked to persistent infection with high-risk HPVs 
and is generally preceded by a long latency period. However, only a minority of woman infected 
with HPVs develop cancer. These observations strongly suggest that accumulation of host 
genetic changes and predisposing host factors play a central role in malignant progression of 
high-risk HPV associated lesions (Stanley et al., 2004). 
Infection with the high-risk HPV type -16 and -18, results initially in unobtrusive squamous 
intraepithelial lesions (SIL) in women. Most of the lesions are cleared 6-12 months after 
appearance, possibly due to the host immunological defence. A small percentage progresses to 
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high-grade SIL (HSIL), carcinoma in situ and without surgical interference to squamous-cell 
carcinoma or adenocarcinoma of the cervix (zur Hausen 2000 and 2002).  
 
1.3 Functional organization of the HPV Genome  
 
Papillomaviruses are a group of small non-enveloped viruses with 55 nm diameter icosahedral 
capsids. The supercoiled, circular DNA of human papillomavirus (HPV) genome contains 
between 6800 and 8000 base pairs and can be divided into three major regions: early, late and 
long control region (LCR) (zur Hausen et al., 2002).  
 
1/7857
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Figure-1.1: The organization of circular 
HPV 18 DNA 
Schematic overview of genome 
organization of HPV-18. E1-E7 are coding 
for the ‘early’ (E) genes. L1 and L2 coding 
for the ‘late’ (L) genes. Viral transcripts, 
uniformly span the E6 and E7 region, and 
are often linked to flanking cellular 
sequences. A non-coding 800-bp fragment, 
called upstream regulatory region (URR) 
or long control region (LCR), is located 
upstream of E6 gene, and controls both 
viral transcription and DNA replication 
(Cole and Danos, 1987). 
 
These three regions are separated by two polyadenylation (pA) sites: early pA (AE) and late pA 
(AL) sites (Zheng and Baker, 2006). The early region of the papillomavirus genome encodes six 
open reading frames (ORF), (E1, E2, E4, E5, E6 and E7), that translate individual proteins for 
‘early’ (E) functions. The late region of all HPV genomes, encodes L1 and L2 ORFs, for 
translation of major (L1) and minor (L2) capsid protein. The LCR contains the origin of 
replication (ori) and numerous cis and trans elements that are necessary to regulate viral 
transcription and replication. A notable feature of all papillomavirus genes transcripts is that they 
are transcribed as a bicistronic or polycistronic mRNA containing two or more ORFs which are 
polyadenylated at either an early or late poly (A) site (Desaintes and Demeret, 1996; Zheng and 
Baker, 2006).  
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Papillomaviruses replicate and assemble exclusively in the nucleus. Papillomaviruses infect the 
basal keratinocytes basal layers of the stratified squamous epithelium. In the course of cancer 
development, the viral molecule frequently is integrated into host-cell DNA.  
This integration is accompanied with disruption of the E2 coding region, resulting in an 
uncontrolled E6/E7 expression.  The viral transcripts, which uniformly span the E6 and E7 
region, and are often linked to flanking cellular sequences, are present and transcription might be 
modulated (enhanced) by flanking host-cell promoters (Zheng and Baker, 2006; Barksdale et al., 
1993; zur Hausen, 2002).  
                                                                                                                      
1.4 HPV oncoprotein and their transformation capacity 
 
The high-risk HPVs associated with malignant progression are capable of transforming a variety 
of cells in tissue culture, including primary human squamous epithelial cells.   
A number of cell lines have been established from cervical carcinoma tissue samples. A high 
percentage of these cells have been shown to contain HPV16 or HPV18 DNA which is generally 
transcriptionally active (Werness et al., 1991; Howley et al., 1991a and 1991b). 
One of the key events of HPV induced carcinogensis is the integration of the HPV genome into a 
host chromosome. HPV genome integration occurs near common fragile sites of the human 
genome (Thorland et al., 2003). This integration leads to constitutive expression of E6 and E7 
oncoprotein, whereas other portions of the viral DNA are deleted or their expression is disturbed. 
For example, loss of the HPVE2 transcriptional repressor is significant, and results in 
deregulated HPV E6 and E7 expression. Cells that express E6 and E7 from integrated HPV 
sequences have a selective growth advantage compared to cells with episomal HPV genomes 
(Jeon et al., 1995).  
High-risk HPVs encode for at least three proteins with growth-stimulating and transforming 
properties: E5, E6, and E7 oncoprotein. E5 protein appears to be important in the early course of 
infection and is expressed in productive infections. The E5 region encodes a hydrophobic protein 
which is preferentially found in Golgi apparatus and plasma membrane. It stimulates cell growth 
by forming a complex with the epidermal-growth factor receptor, the platelet-derived growth-
factor-β receptor, and the colony-stimulating factor-1 receptor (DiMaio and Mattoon, 2001). In 
addition, it has been shown to prevent apoptosis due to DNA damage. After integration of the 
viral genome into the host cell chromosome the open reading frame coding for E5 is frequently 
deleted in cervical carcinoma cells. This demonstrates that E5 is not necessary to maintain the 
transformed phenotype (Genther et al., 2003; Münger et al., 2004).  
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A more significant role for malignant transformation can be assigned to E6 and E7 proteins 
(Münger and Howley, 2002). E6 and E7 are consistently expressed in malignant tissue culture 
and inhibiting their expression blocks the malignant phenotype of cervical cancer cells (zur 
Hausen, 2002; Münger et al., 2004). The oncogenic potential of human papillomaviruses (HPVs) 
is reflected in vitro by their ability to immortalize keratinocytes and to change their 
differentiation behaviour (Schlegel et al., 1988). They are independently able to immortalize 
various human cell types in tissue culture, but efficiency is increased when they are expressed 
together (Hawley-Nelson et al., 1989; Watanabe et al., 1989; Münger et al., 1989a; McDougall et 
al., 1994).    
 
1.4.1 The high–risk E6 oncoprotein and its biological activities 
 
The full length HPV E6 genes encode an approximately 160 amino acid protein (18 kDa) and 
contain two domains consisting of Cys-XX-Cys-X29-Cys-XX-Cys, which are expected to be 
involved in zinc binding (Barbosa et al., 1989; Grossman and Laimins 1989). E6 is involved in 
the viral life cycle, blocks apoptosis, alters the transcription machinery disturb cell-cell 
interactions and increases life span of the cells (Münger and Howley, 2002). It binds physically 
to p53, CBP/p300, E6 associated protein (E6-AP), E6 binding protein (E6-BP), paxilin, Bak, Tyk 
2 and interferon regulatory factor-3 (IRF-3) (Chakrabarti and Krishna, 2003). 
Indeed, some of the prominent functions of the E6 protein originate from its interaction and 
degradation of p53 (Werness et al., 1990; Howley et al., 1991b) and the pro-apoptotic protein 
BAK (Jackson et al., 2000), which results in resistance to apoptosis and an increase in 
chromosomal instability. p53 is tumor suppressor protein (Vogelstein et al., 1990) which is 
induced in response to cellular stress such as UV-irradiation, hypoxia or viral infections while  
p53 expression can also be increased by posttranslational stabilization, leading to arrest in G1 
(Kuerbitz et al., 1992). The p53-G1 block enables the repair of damaged DNA before proceeding 
in the cell cycle (Lane et al., 1992). p53 activation can stimulate the expression of the genes 
involved in cell cycle and apoptosis, such as of the cyclin-dependent kinase inhibitor p21WAF/CIP. 
E6 mediated degradation of p53 (Scheffner et al., 1990) involves the cellular protein E6-AP 
(Huibregste et al., 1993) which acts as an E3 ligase (Scheffner et al., 1993). Only in the presence 
of the E6 protein E6-AP can degrade p53; resulting in uncontrolled proliferation. p14ARF, an 
alternate gene product of p16INK4a, described as a tumor suppressor, induces p53-dependent cell 
cycle arrest causing elevated levels of p21 (Stott et al., 1998). E6 can overcome this arrest signal 
in a p53 dependent mechanism that involves the repression of the cyclin B and cdc2 promoters 
(Passalaris et al., 1999). E6 has been implicated to prevent apoptosis also in a p53 independent 
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pathway via binding the Bak protein, a proapoptotic member of the Bcl-2 family. The 
degradation of the Bak protein via the proteasome involves also the recruitment of the E6-AP 
(Thomas and Banks et al., 1998 and 1999).  
HPV E6 is capable of altering the transcription of target promoters in a positive or negative 
manner such as the HPV early promoter in the upstream regulatory region (URR) (Gius et al., 
1988). It can also bind to and inhibit the transcriptional co-activators like CREB-binding protein 
(CBP) and p300, thereby abrogating the transcriptional activation of p53 (Patel et al., 1999; 
Zimmermann et al., 1999). Furthermore E6 can stimulate the transcription of VEGF, (the most 
important inducer of angiogenesis) (Lopez-Ocejo et al., 2000) due to the positive impact on the 
activity of other transcription factors such as Sp-1 (Gille et al., 1997). 
Furthermore the high risk HPVE6 contain a carboxyl terminal PDZ domain binding protein 
motive X-(S/T)-X-(V/I/L)-COOH and can bind a number of cellular PDZ domain containing 
proteins, such as hDLG (human homologue of the drosophila melanogaster tumor suppressor 
protein), MAGUK (member of membrane associated guanylate kinase) etc. (Kiyono et al., 1997; 
Nakagawa and Huibregste 2000) and promotes their degradation by E6-AP recruitment (Gardiol 
et al., 1999; Glaunsinger et al., 2000). PDZ containing proteins are involved in negatively 
regulating cellular proliferation. It is conceivable that interaction with PDZ proteins may 
contribute to the transforming activities of high-risk HPV E6 proteins. 
In addition, the activation of telomerase and the postulated inhibition of degradation of Src-
family kinases by the E6 oncoprotein seem to fulfil important functions in growth stimulation 
(Veldman et al., 2001; Oda et al. 1999). It is speculated that the stabilization of the activated 
forms of specific members of the SRC family of kinases could contribute to the HPV-
transformed phenotype (Oda et al., 1999).  
 
1.4.2 The high-risk HPV E7 oncoprotein and its biological activities  
 
HPV E7 proteins are low-molecular-weight proteins of approximately 100 amino acids and 
predominantly localised in the nucleus (Greenfield 1991). Like other oncoproteins encoded by 
small DNA viruses, they associate and modify the function of cellular protein complexes.  
The amino terminal domain of HPV E7 is composed of two conserved region: (CR1 and the CR2 
which have sequence similarity to a small portion of adenovirus E1A and with SV40 T (Smian 
Virus-40 T antigen). The HPV E7 carboxyl terminus contains a zinc-binding domain consisting 
of two copies of a Cys-XX-Cys motif which are separated by a 29-amino-acid spacer acting as a 
dimerisation/multimerisation domain (Clemens et al., 1995) (Represented in result Figure 3.13).  
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HPVE7 proteins are phosphoproteins (Smotkin and Wettstein 1987) and contain a casein kinase 
II consensus phosphorylation site in their amino terminal site (Barbosa et al., 1990). An 
additional carboxyl terminal phosphorylation site has been described but the protein kinase that 
targets this site is unknown (Massimi and Banks, 2000).   
The CR2 region contains a conserved LXCXE sequence which interacts with the retinoblastoma 
tumor suppressor protein pRb and the related “pocket proteins” p107 and p130 (Dyson et al., 
1989 and 1992). These proteins interact with the transcription factor E2F, which is able to 
regulate cell cycle transition (Chellapan et al., 1991; Hiebert et al., 1992; Zhu et al., 1995; Cam 
et al., 2003). The association between E2F and pocket proteins prevents the binding of E2F to 
target promoter sequences and therefore represses genes involved in cell cycle progression and 
DNA replication (Macaluso et al., 2005). 
This interaction between E7 and pRb is critical for the maintenance of the transformed 
phenotype while high-risk HPV E7 has a higher affinity to pRb than low-risk HPV E7 protein 
(Münger et al., 1989b; Gage et al., 1990). Several studies have demonstrated that disruption of 
the E7-pRb interaction is accompanied by a loss of cellular transformation (Barbosa et al., 1990; 
Heck et al., 1992; Sang and Barbosa, 1992).  
In addition to pRb binding and degradation, E7 has other cellular target proteins, including 
transcription factors, cell cycle regulators, and metabolic enzymes. The interaction with these 
proteins need the carboxyl-terminal domain (Münger et al., 2001) which contributes to 
association with chromatin-modifying enzymes, such as histone deacetylases and histone acetyl 
transferases (Brehm et al, 1999a). E7 interacts with the transcriptional co-activators p300, CBP, 
and pCAF (Huang and McCance, 2002; Avvakumov et al., 2003; Bernat et al., 2003).  
 
1.4.2.1 Control of the cell cycle and its disruption by high-risk HPV E7  
 
Cell cycle control is regulated by the activity of cyclin-dependent kinases (CDKs) and their 
activating coenzymes, cyclins. The activity of CDKs (CDK1, CDK2, CDK4, CDK6) is regulated 
by the abundance of their activating partner cyclins (Cyclins A, B, D, E), phosphorylation by 
various kinases and interaction with CDK inhibitory proteins (CDKIs) (Sherr et al., 1995a; 
Beijersbergen and Bernards 1996). Two classes of mammalian cyclin-dependent kinase 
inhibitors have been described: The CIP/KIP family, comprised p21, p27, and p57, and the INK4 
family, comprised of p15, p16, p18, and p19 (Sherr and Roberts, 1995b). Generally CDKs, 
cyclins, and CDK inhibitors function within several pathways, including the p16INK4A-cyclin D1-
CDK4/6-pRb-E2F, p21WAF1-p27KIP1-cyclin E-CDK2, and p14ARF-MDM2-p53 pathways (Kim and 
Zhao, 2005). The INK4 molecules specifically inhibit cyclin D complexes by interaction with 
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CDK4 and CDK6 components. The KIP family is affecting cyclin E, cyclin A/CDK2, and cyclin 
B/CDK1 by binding both the cyclin and CDK subunit. Alteration in CDKs, CDKIs, and cyclins 
can lead to uncontrolled proliferation and might contribute to malignant of the uterine cervix 
(Sherr and Roberts, 1995b). 
In many cancers and cancer cell lines the mechanisms which control the growth and 
differentiation mechanism are disrupted or at least impaired (Sherr et al., 1996). Considering that 
HPV infected and HPV E6/E7 oncogene expressing cervical cancer cells display aberrant 
regulation of the cell cycle, due to interaction with cell cycle regulatory proteins, such as cyclin 
A, cyclin E, p16, p21 and p27 is a characteristic feature (Kim and Zhao, 2005; Tommassino et 
al., 1995). 
In a dividing cell, mitogenic stimulation leads to synthesis and assembly of cyclin D/CDK4 
complexes, which contribute to the phosphorylation and consequent inactivation of pRb, 
increased expression of cyclin E, sequestration of cdk2 inhibitors of the Cip/Kip family. Cyclin 
E/CDK2 continues to inactivate Rb and also phosphorylates substrates important for DNA 
synthesis and S phase entry. CyclinA-CDK2 is assembled during S phase and remains active 
through G2 phase (Sherr et al., 1993; Sherr and Roberts, 1999). 
E7 affects these cyclin-CDK complexes by deregulating transcriptional levels of cyclin E due to 
loss of E2F mediated repression; but also by affecting the posttranscriptional levels of cyclin E 
(Zerfass et al., 1995; Botz et al., 1996; Martin et al., 1998). E7 protein has been shown to bind to 
cyclin A-cdk2 in a cell cycle dependent manner, with maximal activity in the S and G2 phases 
(Tommassino et al., 1993).  
The cyclin A-CDK2 interacts and phosphorylates E2F, leading to its loss of DNA binding 
capability. Hence interaction of E7 with cyclin A/CDK2 prevents the inactivation of E2F and 
thereby permitting the cell to bypass normal checkpoints with consequent loss of DNA 
replication fidelity, explaining increased chromosomal abnormalities (White et al., 1994). 
HPVE7 can override growth-inhibitory activities of cyclin dependent kinase inhibitors, including 
p21CIP1/WAF1 and p27KIP1 (Jones et. al., 1997; Zerfass-Thome et al., 1996). Since these proteins 
are critical regulators of cell cycle arrest during keratinocyte differentiation (Missero et al., 
1996), their inhibition by E7 may also contribute to the maintenance of a replication-competent 
cellular milieu in differentiated host epithelial cells (Cheng et al., 1995). A carboxyl-terminal E7 
domain that does not contribute to pRb binding and/or degradation is necessary for the ability of 
E7 to override p21-mediated growth arrest (Helt et al., 2002). The association with p21 abrogates 
its activity to inhibit cyclin/CDK activity as well as PCNA-dependent DNA replication (Funk et 
al., 1997; Jones et al., 1997). Since p27 has been implicated as a mediator of cellular growth 
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inhibition by TGF-β in keratinocytes, this activity may contribute to the ability of cellular growth 
inhibition by TGF-β-associated growth arrest (Pietenpol et al., 1990). 
E7 oncoprotein mediated degradation of pRb releases the transcription factor E2F from pRb 
inhibition and upregulates p16INK4 (Dyson et al., 1989; Kiyono et al., 1998). The resulting high 
E2F activity might lead to apoptosis in E7-expressing cells. The upregulation of p16INK4 
counteracts the E6-mediated growth stimulatory function by inactivation of the D-type CDK 
activity (Khleif et al., 1996). Due to direct activation of cyclin A and cyclin E it can bypass this 
inactivation (Zerfass et al., 1995). 
 
1.4.2.2 Binding of High-risk HPVE7 to tumor suppressor protein pRb abrogates the 
control for transition from G1 to S phase during the cell cycle  
 
The tumor suppressor protein pRb is differently phosphorylated during the cell cycle. It is 
present in a hypophosphorylated form during the cell cycle phase G0/G1, at the G1/S boundary it 
is hyperphosphorylated and during late G1, S, G2 and during M phase (Cooper et al., 2001). pRb 
is reconverted to the hypophosphorylated state by specific phosphatases (Ludlow et al., 1993; 
Tamrakar et al., 2000). In-vivo experiments have been shown that hyperphosphorylation of pRb 
occurs on 13 of 16 potential CDK phosphorylation site (Mittnacht et al., 1994; Ezhevsky et al., 
1997 and 2001). Hypophosphorylated pRb represents the active form and inhibits S-phase entry. 
The HPVE7 preferentially forms complexes with hypophosphorylated pRb. This leads to 
inactivation of pRb and permit cells to enter into S phase (Cobrinik et al., 1992).  
The growth suppressive activity of pRb and other pocket proteins (p107 and p130) is mediated 
by members of the E2F family of transcription factors (Cobrinik, 2005). In G0/G1 
hypophosphorylated pRb is bound to E2F (Adams et al., 1995; Du and Pogoriler, 2006). As a 
transcriptional repressor protein pRb bind to E2F via its transcriptional repressor domain (A/B 
and C Pocket, represented in Figure 1.4). Upon phosphorylation by cyclin dependent kinases in 
G1 phase, pRb/E2F complexes dissociate and E2F acts as a transcriptional activator of the cell 
cycle responsive genes (Sherr et al., 1996). 
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Figure-1.2: The HPV E7 abrogates pRb mediated regulation of the G1/S transition of the cell cycle Upon cell 
cycle progression pRb is sequentially phosphorylated by cyclin D/CDK4, cylin E/CDK2 and cyclin A/CDK2. 
Hyperphosphorylated pRb in G1 phase does no longer interact with E2F and free E2F can induce genes which play 
role in cell cycle progression such as DNA polymerase alpha, dihydrofolate reductase, thymidine kinase. The E7 
oncoprotein counteracts the pRb mediated G1-arrest by direct activation of the cyclin/CDK complexes and 
inhibition of the CDK inhibitors p21 and p27 and by proteasomal degradation of pRb (adapted from Christian 
Kuntzen, DKFZ).  
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1.5 The tumor suppressor protein “Retinoblastoma Protein”  
 
1.5.1 The tumor suppressor protein pRb and Cancer 
 
pRb was the first tumor suppressor identified through human genetic studies. The retinoblastoma 
gene is mutated in many human cancers, including retinoblastoma, osteosarcoma and small cell 
lung cancer (Weinberg et al., 1995a).  
Mouse genetic studies revealed that pRb functions are essential for embryonic development. RB-
/- null embryos die at 13.5 day gestation with prominent defects in the central nervous and 
hematopoietic system (Zhu et al., 2005; Jacks et al., 1992; Lee et al., 1992). To this day RB1 
remains the only single gene in which mutation is necessary and sufficient to cause human 
cancer.   
Furthermore, pRb protein can be inactivated by phosphorylation through cyclin–dependent 
kinases (in particular CyclinD/ CDK4) (Du and Pogoriler, 2006). Overexpression of cyclin D1, 
activating mutations in CDK4/6, and inactivating mutations in the cyclin D/CDK4 inhibitor 
p16INK4a are frequent events in various human cancers (Kim and Zhao et al., 2005). Since most, 
if not all, human cancers have one or more of these events it has been proposed that disruption of 
pRb function is a general feature of cancer cells (Sherr et al., 1996). Some immunhistochemical 
studies of pRb in human cancer and in normal tissues, including uterine cervix, have shown that 
pRb is expressed in mature and in differentiated cells (Kim and Zhao et al., 2005).  
 
1.5.2 pRb belongs to the pocket protein family and exerts different function 
 
The Rb protein is a member of a family of three closely related mammalian proteins that 
includes p107 and p130. Together these are often referred to as the ‘pocket proteins’ because 
their main sequence similarity resides in a domain, which mediates interactions with viral and 
cellular proteins, namely the pocket domain (Classon and Dyson, 2001). Altough pRb is the best 
characterised family member (Harbour and Dean, 2000a). The 105 kDa retinoblastoma protein 
(pRb) has been implicated in many cellular processes, such as regulation of the cell cycle, DNA-
damage responses, DNA-repair, DNA-replication, protection against apoptosis and 
differentiation (Classon and Harlow, 2002). 
The most important function of pRb as a tumor suppressor is growth suppression which is 
mediated via interaction with other proteins (Qin et al., 1992; Chow and Dean 1996; Lee et al., 
1998; Morris and Dyson 2001). pRb keeps cells in G1 by repressing the transcription of genes 
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required for cell cycle transition into S phase, and those genes that encode other cell-cycle 
regulators or enzymes required for DNA synthesis. 
The pRb protein is known to bind to more than 100 cellular proteins ranging from transcriptional 
regulators to enzymes involved in signal transduction and chromatin remodelling systems (Lee et 
al., 1998; Rubin et al., 1998; Morris and Dyson, 2001). 
The pRb contains several functional domains. The N-terminal region of pRb amino-acids a 1-
378, has been shown to be important for Sp-1 transactivation as it relieves repression by the 
inhibitor Sp1-I (Kim et al., 1992). Amino acids 379-772 are considered the small pocket domain, 
and are further subdivided by spacer region into A- (amino acids 394-571) and B- (amino acids 
649-773) domains, while the large pocket includes A, B, and C domains. 
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Figure-1.3 Structure of pRb: Numbers at the top of the bar show the amino acids comprising the amino terminus 
(NT), A-pocket (A), spacer region (S), B-pocket (B), C-pocket (C) as well as nuclear localization signal (NLS). The 
consensus cdk phosphorylation sites for serine (S) and for threonine (T) are indicated. The solid lines denote the 
regions of pRb involved in the binding of an inhibitor of Sp1 (Sp1-I), LXCXE-proteins, transcription factor E2F, c-
Abl and MDM2. The LXCXE, E2F, c-Abl and MDM2 binding site comprises the minimal growth suppression 
domain. The consensus cleavage site for the Ced-3/ICE family of proteases (between aa 886D and 887G) is outside 
the minimal growth suppression domain (obtained kindly from Wang et al., 1997). 
 
Domain A is required for an active conformation (Cho et al., 1997) while domain B binds to 
LXCXE motifs in interacting binding proteins like histone deacetylase (HDAC)-1 and HDAC-2, 
ATPase, BRG1, from the SDWI/SNF nucleasome remodelling complex (Brehm et al., 1998; Luo 
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et al., 1998; Magnaghi-Jaulin et al., 1998), D-type cyclins (Weinberg et al., 1995b), the 
transcription factors UBF (Cavanaugh et al., 1995), Elf-1 (Wang et al., 1993) and the 
phosphatase PP1 a type 1 serine/threonine protein phosphatase (Durfee et al., 1993). 
The large pocket of pRb is composed of the A/B region together with the C-pocket amino acids 
773-870 which is most noted for its ability to bind to a class of transcription factors known as 
E2F (Chellappan et al., 1991; Lees et al., 1993). The strongest growth suppressive effects are 
mediated through this interaction.  
The C pocket of pRb is located in the carboxy-terminal region. This region contains binding sites 
for the c-Abl tyrosine kinase MDM2 which are distinct from the E2F site in the carboxy-terminal 
region (Welch and Wang, 1993; Xiao et al., 1995; Hsieh et al., 1999).  
Several of the reported pRb binding proteins have a pro-apoptotic function. For example the 
nuclear c-Abl tyrosine kinase can induce apoptosis due to its kinase activity (Welch and Wang 
1993), which is inhibited by the interaction with pRb (Wang et al., 2000). Furthermore it can 
regulate the stability and apoptotic function of p53 via binding to MDM2 (Hsieh et al., 1999). 
pRb contains several consensus sites for caspase cleavage (Tan et al., 1998; Fattman et al., 2001 
and 1997) on its carboxyl terminus. Degradation of pRb due to caspase function observed in 
response to cell death signals and executing cell killing (Tan et al., 1997). 
 
1.5.3 Regulation of E2F transcription factors by pRb 
 
The pRb lacks the DNA binding domain and is tethered to promoter sequences as a consequence 
of its interaction with other sequence specific transcription factors, such as E2F family proteins. 
Three transcription factors of the E2F family (E2F1, E2F2, E2F3) are the most extensively 
studied targets during the G1 phase. E2F binds to DNA upon heterodimerization with members 
of the differentiation-regulated transcription factor polypeptide (DP) family (Dyson et al., 1998; 
Helin et al., 1998a). The E2F family comprises five members (E2F1-E2F5) all contain an acidic 
activation domain at their C-terminus, required for binding to pRb and transcriptional activation 
(Helin et al., 1993a and 1993b). 
pRb can negatively regulate E2F responsive genes by at least two mechanisms: 
  
I. Binding to the E2F transactivation domain and directly block E2F activity. 
II.  Supressing transcription while tethered to promoters by E2F through recruitment of 
HDACs (Brehm et al., 1998) and the ATP-dependent SWI/SNF complex (Zhang et al., 
2000). 
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Binding of the pRb protein to the promoter through E2F turns off E2F-responsive gene 
transcription. Many of them are essential and rate limiting for the cell to enter into S phase whilst 
during G1 phase they act as negative elements by recruiting the E2F/pRb complex (Zwicker et 
al., 1997). 
Before the cell proceeds to S phase, pRb is phosphorylated at multiple sites by cyclin dependent 
protein kinases (CDKs) resulting in loss of its transcriptional repression activity through the 
dissociation of the E2F-pRb complex, which allows S-phase-specific genes to be transcribed 
(Buchkovich et al., 1989; Classon and Harlow 2002). The importance of the E2F-pRb repressor 
complex for cell-cycle control is highlighted by the fact that pRb mutants isolated from human 
cancer cells fail to bind to E2F (Dyson et al., 1998; Nevins et al., 1992).   
 
1.5.4 Transcriptional repression by the pRb/HDAC/E2F complex  
 
Modification of the DNA structure is critical for regulating gene transcription. One manner in 
which chromatin structure can be altered is by acetylation/deacetylation of histone molecules at 
the nucleosomes. It has been shown, that histone acetyltransferases (HAT) act as transcriptional 
coactivators, by altering chromatin structure, thereby allowing transcription factors to access the 
promoter (Grunstein et al., 1997). In contrast, HDACs have been associated with transcriptional 
inhibition and are found in corepressor complexes.  
Studies on the mechanism of transcriptional repression by pRb revealed, an interaction with 
HDAC1, HDAC 2 and HDAC3 (Brehm et al., 1998; Chen and Wang et al., 2000; Dahiya et 
al.,2000; Magnaghi-Jaulin et al., 1998). The recruitment of HDACs by pRb can reverse histone 
acetylation at promoters and correlates with repression of transcription (Luo et al., 1998). 
E2Fs does not contain LXCXE sequence and bind pRb at a distinct site from the HDACs, 
allowing recruitment of an HDAC-pRb-E2F repressor complex at promoters of cell cycle genes 
(Harbour and Dean 2000a and 2000b). Genes regulated by pRb-E2F repressor and activated near 
G1/S transition appear to require HDAC activity for their repression during mid –G1, suggesting 
that functional HDACs are critical for pRb’s ability to induce G1 arrest (Zhang et al., 2000). 
Furthermore, inhibition of HDACs with trichostatin-A prevents pRb mediated repression of a set 
of cellular genes including cyclin E, suggesting an important role of HDAC activity in pRb 
function (Zhang et al., 2000; Luo et al., 1998). 
The transcriptional repression functions of pRb reside in the pocket domain (residues 379-792) 
and so far all mutations identified in cancer patients, map this region. Several studies with pRb 
mutants containing amino-acid substitutions in the LXCXE-binding site showed no effect on the 
ability of the pRb mutants to inhibit transcriptional activity of E2F, but they were unable to 
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induce growth arrest (Dahiya et al., 2000; Brehm et al., 1998; Magnaghi-Jaulin et al 1998; Dick 
et al, 2000). Furthermore, the pRb-HDAC interaction is targeted by viral oncoproteins such as 
E1A, SV40-T antigen and HPVE7 (Lee et al., 1998; Dick et al., 2000 and 2002). This indicates 
that the pRb-HDAC interaction, mutation of the pocket or oncoprotein action correlates with 
progression into S-Phase.  
 
Figure-1.4: pRb-mediated repression of chromatin during the cell cycle.  
Prior to the G1-S transition, phosphorylation of pRb by CDKs, or displacement of HDACs by viral oncoproteins, 
such as E7, leads to dissociation of the E2F-pRb-HDAC repressor complex. E2F is then free to activate transcription 
by contacting basal factors or by contacting histone acetyltransferases, such as CBP, that can alter chromatin 
structure (Trouche et al., 1996; Trouche and Kouzarides 1996). HDAC: histone deacetylases; DP: differentiation-
regulated transcription factor polypeptide, CDK: cyclin-dependent kinases, TFs: Transcription factors. ‘Ac’ denotes 
acetylated lysine residues (obtained kindly from Brehm et al., 1998). 
 
A repressor complex containing hypophosphorylated pRb and HDACs forms early in G1 phase. 
This complex interacts with E2F that is bound to S-phase-specific promoters. HDAC then 
deacetylase the nucleosomes surrounding the promoter and thereby induces a change in 
chromatin conformation. The now-repressive chromatin denies transcription factors access to 
their binding sites, and transcription is shut off.  
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1.6 Chromatin regulation and the role of HDAC inhibitors  
 
1.6.1 Chromatin regulation by HATs and HDACs  
 
In eukaryotic cells DNA is condensed around nucleosomes. Nucleosomes are the regularly 
repeating units of chromatin in which 146 base pairs of DNA are tightly wrapped around the 
core histone octamer (Luger et al., 1997). Each nucleosome contains two units of core histone 
H2A, H2B, H3 and H4. The nucleosomes are also connected to their neighbour by a short 
segment of linker DNA (approximately 10 to 80 base pair) which is bound and stabilized by 
histone H1 protein.  
Posttranslational covalent modifications of the N-terminal histone tails of nucleosomes, 
acetylation/deacetylation of lysines, methylation of lysines or arginines, phosphorylation of 
serines and threonines, ubiquitylation and sumoylation of lysines, and ADP-ribosylation of 
glutamic acids (Felsenfeld et al., 2003; Khorasanizadeh et al., 2004) all regulates gene 
expression. 
These modifications determine the status of the chromatin (Jenuwein and Allis 2001; Agalioti et 
al., 2002; Richards and Elgin et al., 2002) and regulate the access of the transcription-regulatory 
complexes to the DNA (Jenuwein and Allis 2001; Turner et al., 2003). 
Histone acetyltransferases (HATs) and histone deacetylases (HDAC) are the two classes of 
enzymes that mediate the acetylation and deacetylation of histones (Marks et al., 2004). In 
general, increased histone acetylation is associated with open and active chromatin status which 
leads to enhanced transcription while deacetylated histones are associated with condensed 
chromatin and transcriptional repression. HATs and HDACs are also recruited to gene promoters 
by multiprotein transcriptional complexes, where they regulate transcription through chromatin 
modification without directly binding the DNA (Cress and Seto, 2000; Lindemann et al., 2004). 
Additional HDACs exist also in large multimeric complexes that are recruited to the gene 
promoters by co-repressors, which are associated with transcription factors (Feinberg et al., 
2004). Importantly HATs and HDACs have also been shown to affect the acetylation status of 
lysines in transcription factors. (e.g p53, E2F, GATA1, relA, YY1, Mad/Max, TFII and TFIIF, 
and hormone receptors), which may affect their DNA binding and transcriptional activity 
(Bolden et al., 2006; Minucci and Pelicci, 2006). In addition it has been shown that non-
transcriptional factors such as cytoskeleton protein α-tubulin, nuclear import protein importin-α-
7, DNA repair protein Ku70 and heat shock protein 90 can be deactylated by HDAC molecules 
(Bannister et al., 2000; Blander, 2002; Haggarty et al., 2003; Cohen et al., 2004). 
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HATs can be divided into subfamilies based on the presence of highly conserved structural 
motifs. These include the GNAT, MYST, and the p300/CBP subfamilies (Johnstone et al., 2003). 
The p300/CBP family does not bind directly to DNA but is recruited to promoters by DNA-
bound transcription factors (Roth et al., 2001).  
The HDAC family is divided into Zn-dependent (Class I and Class II, Class IV) and Zn-
independent NAD-dependent (Class III) enzymes (Cheng et al., 2003). The class I HDACs (1, 2, 
3, and 8) are ubiquitously expressed and located in the nucleus (De Ruijter et al., 2003) while 
class IIa HDACs (4, 5, 6, 7, 9, and 10) can shuttle between the nucleus and the cytoplasm. The 
class IIb HDACs, HDAC6 and HDAC10, are found in the cytoplasm and contain two 
deacetylase domains. HDAC6 has a unique substrate specifity conferred by with α-tubulin 
deacetylase domain (Bolden et al., 2006). HDAC 11 is the sole member of the class IV HDACs, 
which shares sequence similarity with the catalytic core regions of both class I and II enzymes 
(Gao et al., 2002).  
 
1.6.2 Inhibitors of HDAC molecules  
 
Structurally diverse classes of HDACi were classified as either products isolated and purified 
from natural sources or synthetically produced compounds. Based on theirs chemical structure 
HDAC inhibitors can be divided into six classes. These include the hydroxamic acid derivatives 
(TSA, SAHA, Oxamflatin), short-chain fatty acids (sodium butyrate, valproic acid, 4-
phenylbutyrate), Synthetic pyridyl carbamate derivative (MS-275), Synthetic benzamide 
derivatives (CI-994 (N-acetyldinaline)), electrophilic ketones (trifluoromethyl ketone) and cyclic 
peptides (trapoxin, depsipeptide). These compounds have a polar end and can block the catalytic 
activity of the HDAC pocket structure by chelating zinc ion or other part produce effect through 
block passage of active site (Finnin et al., 1999; Marks et al., 2004). 
The various HDAC inhibitors studied so far have been shown to inhibit class I (HDACs 1, 2, 3, 
and 8) and class II a (HDACs 4, 5, 6, 9, and 10), although only the hydroxymic acid analog 
HDACi like TSA, have been shown to inhibit class II b (HDACs 6 and 10). Class III HDACs 
(SIR T1, 2, 3, 4, 5, 6, and 7) known as sirtuins, require NAD+ rather than zinc as a co-factor for 
their activity, and are not inhibited by commonly used HDAC inhibitors.  
 
1.6.3 HDAC inhibitor induced cellular effects 
 
HDAC inhibitors (HDACi) can mediate a diverse range of intrinsic effects on cell growth, 
differentiation or apoptosis and survival in-vivo and in-vitro. These effects are dependent of the 
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cell type and concentration used. In some cases, growth arrest is induced at low doses, and 
apoptosis is induced at higher doses; in other cases growth arrest precede apoptosis. The 
molecular mechanisms behind these biological effects are not completely understood. 
 
1.6.3.1 Influence of HDAC inhibition on gene transcription 
 
The mechanism of the antiproliferative effects of HDAC inhibitors involves, either by directly 
affecting chromatin structure or the activity of transcription factors. Recent cDNA microarray 
studies have shown that treatment with HDACi modulates the expression of a selective subset of 
genes consisting of approximately 20 % of all genes in different cell types (Glaser et al., 2003; 
Mitsiades et al., 2004; Peart et al., 2005). A significant number of apoptotic (i.e., CD95, CD95 
ligand, gelsolin, Bak, Bcl-XL) and cell cycle regulatory genes (i.e., cyclin D, cyclin E, cyclin A, 
p21WAF/CIP1), have been identified (Huang et al., 2000; Mariadason et al., 2000; Chen et al., 2002; 
Johnstone et al., 2002; Henderson et al., 2003) to be activated or repressed by different HDACi. 
Importantly, activation of some genes by HDACi involves the Sp1 site in the promoter region, 
which recruits the HDAC containing transcription complex. Therefore treatment with HDACi 
induced the acetylation of these genes which are involved in growth arrest, differentiation and/or 
apoptosis (Huang et al., 2000; Takakura et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1.5: Proposed mechanism of action of histone deacetylase inhibitors.  
Histone deacetylases: HDAC Transcription factor complex (TFC), Ac: acetyl group, HAT: histone acetyltransferase. 
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1.6.3.2 HDAC inhibitor and cell cycle  
 
In general, treatment with HDAC inhibitors induces cell cycle growth arrest in G1 or G2/M, 
differentiation and/or apoptosis of transformed cells (Bhalla 2005). All HDACi studied to date, 
with exception of tubacin, can induce cell cycle arrest at G2/S boundary mediated by the 
retinoblastoma protein pRb, p107 and p130 (Haggarty et al., 2003). The HDACi mediated 
induction of p21 correlates with an increase in the acetylation of histones associated with p21 
promoter region (Richon et al., 2000; Lagger et al., 2002; Gui et al., 2004). Activation of p21 
occurs in a p53-independent manner which promotes hypophosphorylation of pRb (Richon et al., 
2000). 
Additionally the repression of cyclin D and cyclin A contributes to the loss of CDK2 and CDK4 
kinase activities and hypophosphorylation of pRb (Kim et al., 1999; Qiu et al., 2000; Sandor et 
al., 2000). Surprisingly, HDACi often transactivate cyclin E, although this is not associated with 
increased CDK2 activity, most likely due to the concomitant increase in p21 levels (Kim et al 
1999; Sambucetti et al., 1999; Sandor et al., 2000). HDACi induced transcriptionally repression 
of genes involves the CTP synthase and thymidylate synthetase, which play role in DNA 
synthesis and by progression of S phases (Glaser et al., 2003). 
Since most of the tumor cells have a defective G2-phase checkpoint, HDACi can mediate G2/M 
phase arrest by activating a G2-phase checkpoint. Although this is a much rarer event then 
HDACi mediated G1 arrest (Qiu et al., 2000; Burgess et al., 2001).  
 
1.6.3.3 HDAC inhibitor induced apoptosis 
 
The therapeutic potential of HDACi stems from their capacity to selectively induce apoptosis 
(Marks et al., 2005). The clinical trials and preclinical animal experiments clearly show that 
HDACi can have potent anticancer activities at concentrations that are minimally toxic to the 
host (Kelly et al., 2005; Drummond et al., 2005; Dokmanovic et al., 2005).  
Treatment with HDAC inhibitors triggers both the intrinsic, and the mitochondria-initiated 
signalling for apoptosis (Johnstone et al., 2003; Lindemann et al., 2004).  
 A large number of proapoptotic genes (Bak, Bax, CD95, CD95 ligand, gelsolin, p53, caspases-9, 
caspase-8, Apaf-1, p53, caspase-3, Bim, Bid, Bad), and repression of anti-apoptotic genes (Bcl-
2, Bcl-XL, c-FLIP, surviving, XIAP, NFκB; Mcl-1) was demonstrated after treatment with 
HDAC inhibitors (Johnstone et al., 2003; Chen et al., 2002; Henderson et al., 2003; Zhang et al., 
2003).   
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A large number of independent studies strongly support a role for the mitochondrial pathway in 
HDACi-mediated tumor cell death via induction of BCL2 or BCL-XL, which block the intrinsic 
apoptotic pathway (Ruefli et al., 2001; Peart et al., 2003; Johnstone et al., 2002; Mitsiades et al., 
2003; Henderson et al., 2003). Several types of HDACi especially the hydoxamic acid analogs, 
have been shown to participate in mitochondrial permeability transition. They release pro-
apoptotic molecules such as cytochrome c, Smac, and Omi into the cytosol, thereby triggering 
the activity of the Apaf-1”apoptosome”, which leads to the processing and activation of caspase-
9 and -3 (Marks et al., 2003; Fuino et al., 2003;Guo et al., 2004). 
The proapoptotic Bcl-2 (BH3 only proteins) family member Bid is also cleaved and activated in 
response to various HDACi (Ruefli et al., 2001). Nevertheless HDACi triggered intrinsic 
apoptotic cascade is a major question that remains to be fully answered. One possibility is that 
HDACi induce global changes in gene expression that alter the balance of expression of pro- and 
anti- apoptotic genes in favour of a pro-apoptotic biological response.   
 
1.6.4 HDAC inhibitors and treatment of cancer  
 
Inhibitors of HDAC are promising as single-agent anti-cancer drugs, which are highly effective 
in up-regulating tumor suppressor gene expression, reducing tumor growth and inducing 
programmed cell death in vitro and in cancer patients in phase I and II clinical trials (Liu et al., 
2006). 
HDAC inhibitors such as Trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and 
sodium butyrate (SB), can inhibit cancer cell growth in vitro (Yoshida et al., 1990; Wharton et 
al., 2000) and in vivo (Vigushin et al., 2001; Yoshida et al., 1990), reverse oncogene-
transformed cell morphology (Kwon et al., 1998; Marks et al., 2000), and enhance cell 
differentiation (Kosugi et al., 1999; Zhou et al., 2000). 
Sodium Butyrate is the first confirmed HDAC inhibitor and belongs to the natural short-chain 
fatty acid; produced by bacteria in colon (Newmark et al., 1994). It has been demonstrated to 
induce growth arrest in vitro and differentiation in vivo and in vitro in several cancer cells like 
human myeloid leukaemia cells (Rosato et al., 2001; Chen et al., 1994), MCF-7 breast carcinoma 
cells (Heerdt 1999) and colon carcinoma cells (Hodin et al., 1996; Litvak et al., 1998). SB 
induced growth inhibition and cell death both in vitro and in vivo in prostate cancer cells (Maier 
et al., 2000; Kuefer et al., 2004). Furthermore, it induced apoptosis in human myeloma cells 
(Lavelle et al., 2001), and growth arrest and apoptosis in colon cancer cells (Archer et al., 1998; 
Mahyar-Roemer et al., 2001). The mechanism by which n-butyrate causes cell cycle arrest and 
apoptosis are not fully understood but involve at least in part the p21WAF-Rb-E2F pathway. 
 
Introduction                      30 
Another frequent HDAC inhibitor is TSA, derived from the metabolic product of streptomycete 
(Chen et al., 2004). TSA belongs to the group of the hydroxamic acid derivatives which contain 
a functional group that interacts with the critical zinc atom at the base of the catalytic pocket of 
the class I and II HDACs (Marks et al., 2000 and 2001).  
Exposing A2780 ovarian cancer cells with TSA produced a marked change in cellular 
morphology, proliferation, and differentiation (Strait et al., 2002). TSA and SB blocked two 
colon cancer cell lines (SW1116 and Colo-320) mainly in the G1 phase. In these human cancer 
cell lines, increased acetylation of the gene-associated histones, and a G1 cell cycle arrest was 
also observed (Chen et al., 2004).  
Clinical trials show that HDAC inhibitors are well tolerated and can inhibit HDAC activity in 
peripheral mononuclear cells and tumors. More importantly, they display clinical activity with 
objective tumor regression. HDACi induce equivalent histone hyperacetylation and induction of 
p21 in both normal and tumor cells while normal cells undergo cell cycle arrest at the G1/S 
checkpoint in response to HDACi, they are largely insensitive to HDACi-induced apoptosis (Qiu 
et al., 1999; Zhang et al., 2003). How HDAC inhibitor are selectively cytotoxic against tumor 
cells, whilst leaving normal cells apparently unharmed remains to be determined. 
Several HDAC inhibitors are currently in clinical trials including butyrates, valproic acid, 
SAHA, pyroxamide, depsipeptide, MS-275 and CI-994. These HDAC inhibitors are in phase I 
and II evaluation as monotherapy, as well as in combination with other differentiation therapies 
and cytotoxins. Warrel et al., (1998) first used HDAC inhibitor for treatment of acute 
promyelocytic leukaemia patients. After solo all-trans retinoic acid treatment (ATRA); sodium 
phenylbutyrate and ATRA were applied for combined chemotherapy, next bone marrow report 
showed leukaemia cells were cleared and reached complete remission ten days later (He et al., 
2001). 
HDACi have been shown to function synergistically with structurally and functionally diverse 
chemical compounds such as Hsp90 inhibitor geldanamycin (17-AAG) (Rahmani et al., 2003; 
George et al., 2005; Rahmani et al., 2005), proteasome inhibitor bortezomib (Pei et al., 2004; 
Hideshima et al., 2005; Nawrocki et al., 2006) and biologically active polypeptides (Lindemann 
et al., 2004; Bhalla, 2005), but the mechanistic basis for this synergy has not been fully 
elucidated.  
An important finding in predicting the potential utility of HDAC inhibitors in the clinic is their 
activity in cell-lines that are resistant to existing chemotherapeutics. For example Gleevec-
resistant Bcr/Abl human chronic myelogenous leukaemia (CML) cells are sensitised to Gleevec 
upon co-treatment with SAHA (Yu et al., 2003).  
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                 Figure-1.6: Structure of HDAC inhibitors sodium butyric acid and Trichostatin A 
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Aim of this study: 
 
Our Group has maintained a long standing interest in analysing the biologic significance of 
HDACi in HPV transformed cells. Initial observations with SB and TSA on HPV16/18 positive 
cervical carcinoma cells demonstrated growth arrest at the G1 phase of cell cycle progression 
(Finzer et al., 2003). Concomitant with G1 arrest, an increase of the cyclin-dependent kinase 
inhibitors p21 and p27 was also observed, whilst CDK2 activity was suppressed (Finzer et al., 
2001). Moreover longer treatment with these agents sensitized the cells to apoptosis. Among 
these, one of the interesting observations was the enhanced degradation of the pRb while its 
interaction partners HPV E7 and E2F were not affected.  
 
Hence, the aim of this study was to address the following questions: 
1. What is the role of HPV E7 in HDAC inhibitor mediated pRb degradation in cervical cancer 
cells? 
2. Does the tumorigenic phenotype of the target cell plays a role in HDAC inhibitor induced 
pRb degradation? 
3. What is the importance of the direct interaction between HPV E7 and pRb during HDAC 
inhibition? 
4. Which mechanisms play a role in the pRb degradation upon HDAC inhibition? 
5. What is the role of pRb degradation in cell cycle control and apoptosis upon HDAC 
inhibition? 
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II. MATERIALS & METHODS 
 
2.1 MATERIALS 
 
2.1.1 Chemicals and Reagents 
 
[α32 P] dCTP 10 mCi/ml    Amersham, Life Science 
Acetic acid glacial     Merck, Darmstadt 
Acrylamide/ bis acrylamide (29:1), 30%  Sigma, Deisenhofen 
Active charcoal     Serva, Heidelberg 
Agarose      Invitrogen, Karlsruhe  
Amonium acetate     Fluka BioChemika, Deisenhofen 
Ampicillin      Roche Diagnostics, Mannheim 
Amonium persulfate     Sigma, Deisenhofen 
Bacto-Agar      Gibco Life Technologies 
Bacto-Tryptone     Difco, Detroit 
BenchMark (protein marker)    Gibco Life Technologies 
Biogel P30      BioRad, München 
Boric acid      Sigma, Deisenhofen 
Bovine Serum Albumin    Sigma, Deisenhofen 
Bradford Reagent (Bio-Rad Protein Assay)  BioRad, München 
Bromophenol Blue     Sigma, Deisenhofen  
Calcium chloride (dihydrate)    Sigma, Deisenhofen 
Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal 
(MG132)      Calbiochem, Bad Soden 
Chloride acid      Merck, Darmstadt 
Cycloheximide     Sigma, Deisenhofen 
Diethylpyrocarbonat (DEPC)   Sigma, Deisenhofen 
Dimethyl sulfoxide (DMSO)    Merck, Darmstadt 
Dithiothreitol (DTT)     Signa, Deisenhofen 
DNA marker Gene Ruler 1kb DNA ladder  MBI Fermentas,Vilnius 
DNA 6X loading buffer    MBI Fermentas, Vilnius 
Dulbecco’s Modified Eagle’s Medium (DMEM) Gibco, Eggenstein 
E-64       Roche Dignostics, Mannheim 
ECL-Reagent      NEN Lifescience Products Inc 
EDTA       Roche Dignostics, Mannheim 
EGTA       Sigma, Deisenhofen 
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Ethanol absolute     Merck, Darmstadt  
Fetal calf serum     Gibco Life Technologies 
Formaldehyd      Merck, Darmstadt 
Formamide      Fluka BioChemika, Deisenhofen 
[γ32 P] dATP 10 mCi/ml    Amersham, Life Science 
Geneticin (G-418 Sulfate)    Calbiochem, Bad Soden 
Glycerin      Merck, Darmstadt 
Glycine      Sigma, Deisenhofen 
HEPES      Gerbu, Gaiberg 
Hexanucleotide     Amersham-Pharmacia, Freiburg 
Hydrochloric acid     Merck, Darmstadt 
Isoamylalcohol     Merck, Darmstadt 
Klenow Fragment (DNA polymerase I, 5000U/ml) New England Biolabs, Frankfurt 
LB-Medium      Gibco Life Technologies 
Magnesium chloride     Merck, Darmstadt 
2-Mercaptoethanol     Sigma, Deisenhofen 
Methanol      Merck, Darmstadt 
Milk powder      Roth, Karlsruhe 
MOPS       Gerbu, Gaiberg 
Nonidet-P40      Roche Dignostics, Mannheim  
Nucleotides (dNTPs for PCR)   Roche Dignostics, Mannheim 
PBS       Gibco, Eggenstein 
Pefablock SC      Roche Dignostics, Mannheim 
Penicillin [10000U/ml]/Streptomycin [10000µg/ml] Gibco, Life Technologies 
Potassium acetate      Merck, Darmstadt 
Potassium chloride     Merck, Darmstadt 
Potassium hydrogen phosphate   Roth, Karlsruhe 
Potassium hydroxide     Merck, Darmstadt 
2-Propanol, Isopropanol    Merck, Darmstadt 
Random primers     Roche Dignostics, Mannheim 
Restriction enzymes     Amersham-Pharmacia, Freiburg 
RNAse A      Serva, Heidelberg 
Roti-Phenol      Roth, Karlsruhe 
Sodium azide      Sigma, Deisenhofen 
Sodium butyrate     Sigma, Deisenhofen 
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Sodium citrate     Sigma, Deisenhofen 
Sodium chloride     Merck, Darmstadt 
Sodium dihydrogen phosphate (monohydrate) Merck, Darmstadt 
Sodium dodecyl sulphate    Sigma, Deisenhofen 
Sodium fluoride     Merck, Darmstadt 
Sodium ortho-vanadate    Sigma, Deisenhofen 
SuperScript II (RNAse H (-) 200U/µl)  Gibco Life Technologies   
Taq platinum DNA polymerase (5U/µl)  Invitrogen, Karlsruhe 
TEMED      Gibco Life Technologies 
tosyl-L-lysine chloromethyl ketone  
(TLCK)      Roche Diagnostics, Mannheim 
t-RNA       Sigma, Deisenhofen 
Trichostatin A (TSA)     Sigma, Deisenhofen 
Triton X-100       Sigma, Deisenhofen 
Triton X-100 cell lysis buffer (3X)   BD PharMingen, Heidelberg 
Trizma-Base      Sigma, Deisenhofen 
Trypan blue      Sigma, Deisenhofen 
Trypsin/EDTA     Gibco Life Technologies 
Tumor Necrosis Factor-α (TNF-α)   Strahtmann Biotech, Hannover 
Tween 20      Sigma, Deisenhofen 
Urea       Merck, Darmstadt 
 
2.1.2 Laboratory equipment 
 
Analytic Scale AE 160     Mettler, Gießen 
Analytic Scale basic      Sartorius, Göttingen 
Centrifuge 2 K15      Sigma, Deisenhofen 
Centrifuge Biofuge, Varifuge RF    Heraus, Hanau 
Developer machine Curix 60     AGFA 
Electrophoresis camera     Renner GmbH, Dannstadt 
Geiger counter LB 1210B     Berthold, Wildbad 
Gel drier 483       Bio-Rad, München 
Hybridization Oven, Hybrid Mini    Bachofer, Reutlingen 
Incubator (for cells) B5061 EC/CO2, Forma Scientific  Heraeus, Hanau 
Mini-PROTEAN II (minigels western)   BioRad, München 
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Neubauer count chamber     Bender and Hobein, Bruchsal 
PCR Thermo Cycler MultiCycler PTC-2000  M.J. Research 
pH-Meter Calimatic 765     Knick 
Photometer Ultraspec Casette    Amersham-Pharmacia, Freiburg 
Pipette boy acu      Integra Biosciences 
Pipettes p2.5, p10, p20, p200, p1000    Eppendorf, Hamburg 
Power supply EPS 600     Amersham-Pharmacia, Freiburg 
Scale 1216 MP      Sartorius, Göttingen 
Sonifier 250       Branson/Heinemann,  
Schwaebisch Gmünd  
Sterile hood (BioGard Hood)     Baker Company, Sandford 
Thermomixer 5436      Eppendorf, Hamburg 
Trans-illuminator 254-366 nm    Vetter, Wiesloch 
Vortex        Heidolf, Rust  
Water Bath       Julabo, Seelbach 
Western blot transfer camera Hoefer, Semiphor  Amersham-Pharmacia, Freiburg 
        
2.1.3 Solutions and Buffers 
 
Ampicillin     [50 mg/ml] in water, store at -20°C  
 
 
Biogel suspension    1 X TE buffer 
      5 mM sodium chloride 
      0.2 % (w/v) SDS 
      50 % (w/v) Biogel 
 
Blocking buffer (Western Blot)  1 X TBS pH 7.6 
      5 % (w/v) Milk powder 
      0.1 % (v/v) Tween 20 
      Store at 4°C 
 
BSA         [1 µg/µl] in water for protein quantification curve 
Store at -20°C 
 
 
Buffer A (Cytoplasmic protein extraction) 10 mM HEPES pH 7.9 
      10 mM Potassium chloride   
0.1 mM EDTA pH 8.0 
0.1 mM EGTA pH 7.9 
Store at -20°C, 
Before use add protease and  
phosphatase inhibitors 
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Buffer C (Nuclear protein extraction) 20 mM HEPES pH 7.5 
      400 mM Sodium chloride 
      1 mM EDTA pH 8.0 
      1 mM EGTA pH 7.9 
       
 Store at -20°C, 
Before use add protease and 
phosphatase inhibitors 
 
CaCl2 (2M)     147.02 g/mol CaCl2  
      14.7 g CaCl2 resolved in 50 ml H2O 
      Sterile filtration  
 
Chloroform/ Isoamylalcohol (24:1)  24 parts chloroform  
1 part isoamylalcohol 
      Store at 4°C protected from light  
 
Denaturing solution (Southern bot)  0.5 N sodium hydroxide 
      1.5 M sodium chloride 
 
Denhardt’s Solution    5 % (w/v) BSA 
      5 % (w/v) Ficoll type 400 
      5 % (w/v) Polyvinylpyrrolidon 25 
 
DEPC Water     0.1 % (v/v) DEPC  
      1 L water 
 
DMEM complete    500 ml DMEM 
      10 % Fetal Calf Serum 
      100 U/ml Penicillin    
      100 µg/ml Streptomycin 
 
DNA lysis buffer (3X)   1.5 % (w/v) SDS 
      150 mM Tris/HCl pH 7.8    
     150 mM EDTA 
 
DTT      0.1 M stock solution prepared freshly 
 
EDTA      0.5 M EDTA pH 8.0 
 
E64      2.5 mg/ml Stock solution 
 in 50 % ethanol, 50% bidest water 
Store at -20°C 
EGTA      0.25 M EGTA pH 7.9 
 
Freezing medium (cell culture)  10 % (v/v) DMSO 
      30 % (v/v) FCS  
      60 % (v/v) Medium (DMEM) 
      Store at -20°C 
 
 
 
Materials & Methods 38 
G418 (Geneticin sulphate)   [375 mg/ml] stock solution in DMEM complete 
      Store at-20°C 
 
2X HBS Buffer, pH 7.05   3.2 g NaCl 
      0.148 g KCl 
      0,054 g Na2HPO4 x 2H2O 
      0.4 g Dextrose (D (+) Glucose) 
      2 g HEPES  
 
Hybridization solution (Northern and Southern blot) 
      50 % Formamide  
10 U/ml t-RNA 
      5 X SSC 
0.1 % Denhardt’s solution 
50 mM sodium  phosphate buffer pH 6.5 
1 % (w/v) SDS 
 
Hybridization washing buffer (Northern and Southern blot) 
      2 X SSC 
      0.1 % SDS 
 
Laemmli buffer SDS-PAGE (10X)  0.25 M Tris Base 
      1.9 M Glycine 
      1 % (w/v) SDS 
 
LB-Medium     10 g sodium chloride 
      10 g Bacto-Trypton 
      5 g yeast extract 
      add water to 1 liter, pH 7.2 
 
LB-Ampicillin plates    LB-Medium  
      2 % (w/v) Bacto-Agar 
      Add 50 mg ampicillin per liter 
 
MOPS (20 X)     400 mM MOPS  
      100 mM sodium acetate 
 20 mM EDTA 
pH 7.0 (DEPC water) 
Store protected from light 
 
Neutralization solution (Southern Blot) 1 M Tris pH 7.4 
      1.5 M sodium chloride 
 
 
PBS      123 mM sodium chloride 
      17.6 mM di-sodium hydrogenphosphatedihydrate 
      10 mM potassium dihydrogenphosphate 
      pH 7.2-7.8 
 
Pefabloc SC     [23.8 mg/ml] stock solution 
      Store at -20°C 
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RNA loading buffer (2X)   50 % Formamide 
      2.2 M Formaldehyde 
1 % (w/v) Ficoll (type 400) 
      0.02 % (w/v) Bromophenol blue 
      1 X MOPS buffer pH 7.0 
      (DEPC water), Store at -20°C 
 
RNase A     10 mg/ml RNase A 
      10 mM Tris pH 7.5 
      15 mM Sodium chloride 
      80°C /20 min, store at -20°C 
 
SDS      10 % (w/v) in water 
 
SDS total protein extraction buffer  50 mM Tris pH 6.8 
      10 % Glycerin 
      2 % (w/v) SDS 
      0.74 M 2-Mercaptoethanol 
 
SOC medium     2 % (w/v) Bacto-Trypton 
      0.5 % (w/v) yeast extract 
      10 mM NaCl 
      2.5 mM KCl 
      10 mM MgCl2  
      10 mM MgSO4 
      20 mM Glucose 
 
Sodium floride    500 mM Sodium floride 
      Store at -20°C    
 
Sodium ortho-vanadate   10 mM Sodium ortho-vanadate 
      pH 10 Store at -20°C 
 
Sodium Phosphate buffer   1 M sodium dihydrogenphosphate (3 parts) 
      1 M di-sodiumhydrogenphosphate (2 parts) 
      ph 7.0 
 
SSC (20 X)     3 M sodium chloride 
      0,3 M tri-sodium citrate dihydrate 
      ph 7.0 
 
 
 
TAE (50 X)     2 M Tris/HCI 
      0,25 M sodium acetate 
      0.05 M EDTA ph 8.0 
 
TBE (10 X)     0,9 M Tris base 
      0,9 M Boric acid 
      0,02 M EDTA ph 8.0 
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TBS (1 X)     10 mM Tris/HCI ph 7,5 
      100 mM sodium chloride 
 
TBST      1 X TBS ph 7.6 
      0,1 %(v/v) Tween 20 
 
TE (1 X)     10 mM Tris-HCI 
      1 mM EDTA ph 8.0 
 
TNE (1 X)     10 mM Tris/HCI ph 8.00 
      1 mM EDTA 
      100 mM sodium chloride 
 
TNFα      100 U/µl Stock solution 
      10 µg in 200 µl bidest water 
      add DMEM complete to 10 ml 
      Store at - 70C 
 
Towbin (1 X)     25 mM Tris Base 
      192 mM Glycine 
      0.1% (w/v) SDS 
      15 % (v/v) Methanol 
 
Trypan blue     0.25 % in PBS   
 
Western blot loading buffer (5X)  10 % SDS 
      5 mg Bromophenol blue 
12.5 % (v/v) 2- Mercaptoethanol 
      5 mM EDTA pH 8.0 
      50 % Glycerin 
      300 mM Tris pH 6.8 
      Store at -20°C 
 
 
2.1.4 Cell Lines 
 
All cell lines are from human origin and described in detail as follows: 
 
 
HeLa:  Tissue:   adenocarcinoma; cervix 
  Morphology:      epithelial 
  Age stage:  31 years 
  Ethnicity:  Black 
  Growth properities: adherent 
  HPV presence: Type 18 (about 50 copies per cell) 
  Reference:  (Boshart et al. 1984; Schwarz et al.1985)  
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SW756: Tissue:   squamous cell carcinoma; cervix 
  Morphology:      epithelial 
  Age stage:  46 years 
  Ethnicity:  Caucasian 
  Growth properities: adherent 
  HPV presence: Type 18 (12-20 copies per cell) 
  Reference:  (Freedman et al., 1982)  
                                                                                                                                                                             
C33 A: Tissue:   carcinoma; cervix 
  Morphology:      epithelial 
  Age stage:  66 years 
  Ethnicity:  Caucasian 
  Growth properities: adherent 
  HPV presence: negative 
  Reference:  Yee et al. 1985.  
 
HT-3:  Tissue:   adenocarcinoma; cervix 
  Morphology:      epithelial 
  Age stage:  31 years 
  Ethnicity:  Black 
  Growth properities: adherent 
  HPV presence: Type 18 (about 50 copies per cell) 
  Reference:  Boshart et al. 1984; Schwarz et al.1985)  
                                                                                                                                                         
TE-671: Tissue:   adenocarcinoma; cervix 
  Morphology:      epithelial 
  Age stage:  31 years 
  Ethnicity:  Black 
  Growth properities: adherent 
  HPV presence: Type 18 (about 50 copies per cell) 
  Reference:  Boshart et al. 1984; Schwarz et al.1985)  
 
 
444 and CGL-3: Non-tumorigenic and tumorigenic hybrids made between HeLa and human       
fibroblasts, respectively. These were kindly provided by Eric Stanbridge. 
 
 
HPV E6 and E7 immortalised human keratinocytes: Primary human keratinocytes derived 
from neonatal foreskins were immortalized with E6, E7 or both HPV-16 oncogenes after 
infection with amphotropic retroviral vectors (Halbert et al., 1991).  All of these cell lines were 
kindly provided from Dr. Noel Whitaker (DKFZ-Heidelberg). 
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2.1.5 Antibodies 
 
 
primary Antibodies Company Epitope Dilution 
β-Actin, (Clone 4)  
691001 
ICN 
Biotech. 
Chicken gizzard actin as 
immunogen 1:100000 
pRb, Mouse IgG1 
Cat # 554136 (Clone 
G3-245) 
BD, PharMingen 
Epitope between amino acid 
residues 332-344 of human 
Rb 
1:1000 
HPV18E7, Goat-IgG 
Cat# sc-1590 (N-19) 
Santa Cruz 
Biotechnology 
N-Terminus of Human 
papilloma virus type 18 early 
E7 
1:1000 
HPV16E7, Mouse 
(NM2 α- 16E7) 
Obtained from Martin 
Müller, DKFZ Hybridoma supernatant 1:4 
Cyclin E, Mouse-IgG2b  
Cat# sc-247 (HE12) 
Santa Cruz 
Biotechnology  
Recombinant Human cyclin 
E (doublet bands at 50 kDa 
and single band of 42 kDa)  
1:1000 
E2F, Mouse-IgG2a  
Cat# sc-193 (C-20) 
Santa Cruz 
Biotechnology 
Carboxy -terminus of human 
E2F-1 (p60) 1:1000 
p21, CIP1/WAF1 
Mouse-IgG2a (Clone 70) 
Cat# 610233 
BD Transduction 
Laboratories N-terminus of human CIP1 1:500 
PARP-1, Mouse IgG2a  
Cat# sc-8007 (F-2) 
Santa Cruz 
Biotechnology 
Epitope mapping the aa 764-
1014 of C-terminus of 
human origin 
Molecular Weight:116/85 
kDa 
1:1000 
p73, Rabbit polyclonal 
IgG,  
referred: p73SAM  
 
Purified serum was 
kindly obtained from 
A. Emre Sayan, 2005,
Leicester, UK 
Epitope mapping the SAM 
domain (amino acids 487-
554) of human p73 
1:2500 
 
 
Secondary Antibodies Company Epitope Dilution 
Rabbit –IgG-HRP 
Cat# W401B 
Promega conjugated to horse radish 
peroxidase 1:10000 
Mouse-IgG-HRP 
Cat# W4021 
Promega conjugated to horse radish 
peroxidase 1:10000 
Goat-IgG-HRP 
Cat# sc-2020 
Santa Cruz Biotech. conjugated to horse radish 
peroxidase 1:10000 
Mouse isotopic  specific 
IgG1-HRP, cat# sc-2060 
Santa Cruz Biotech. conjugated to horse radish 
peroxidase 1:10000 
Mouse isotopic  specific 
IgG2a-HRP, cat# sc-2060 
Santa Cruz Biotech. conjugated to horse radish 
peroxidase 1:10000 
Mouse isotopic  specific 
IgG2b-HRP, cat# sc-2060 
Santa Cruz Biotech. conjugated to horse radish 
peroxidase 1:10000 
 
Materials & Methods 43 
 
2.1.6 PCR Primers 
 
 
Gene Sequence 
Annealing 
Temperat
ure 
 # of 
cycles 
RB1 
 
For 5’-GGAAGCAACCCTCCTAAACC-3’ 
Rev 5’-TTTCTGCTTTTGCATTCGTG-3’ 60°C 35 
TAp73  
(E. Sayan) 
For 5’-AACCAGACAGCACCTACTTCGACC-3’ 
Rev 5’-GCGACATGGTGTCGAAGGTGGAGC-3’ 62°C 35 
TAp73 
(R. Schmidt) 
For 5’-TGATGGGGGCACCACGTTTGAG-3’ 
Rev 5’-TGTAGTCGTGGCCCTGCTTCA-3’ 56°C 35 
GAPDH For 5’-TGGATATTGTTGCCATCAATGACC-3’ Rev 5’-GATGGCATGGACTGTGGTCATG-3’ 50°C 30 
 
 
2.1.7 Plasmids 
 
 
Plasmid Insert/ target mRNA Sequence References 
pcDNA3.1(-/+) empty 
(5,446 kb) 
Contains CMV, T7 Sp6, SV40 promoter; 
ORF for Amp and Neomycin; origin for 
SV40, ColE1; Poly A site for SV40 and 
BGH and multiple cloning site (MCS). 
M. Müller, 
(Intvitrogen) 
pcDNA3.1/16E7 kozak 
(5,717 kb) 
Contains the HPV16 E7 sequence and an 
additional “Kozak” consensus translation 
inititation site. 
M. Müller 
(DKFZ, Heidelberg) 
 
pSUPER-18E6/E7 
(siRNA) 
 
5′-CCACAACGUCACACAAUGU-3′ 
(HPV18 nt 755–773) 
 
Kuner et al., 2007 
(DKFZ, Heidelberg) 
pSUPER/luciferase 
(siRNA) 
 
5’-CAUCACGUACGCGGAAUAC-`3 
variant:GL2- Photinus pyralis 
 
Butz et al., 2003 
(DKFZ, Heidelberg) 
pSUPER/Empty without any insert Brummelkamp et al., 2002 
 
pEGFP 
(4,7 kb) 
 
enhanced green fluorescent protein gene 
(used as a transfection marker) 
Clontech, 
Laboratories 
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2.1.8 Oligonucleotides for Northern Blot analyses 
 
Gene Insert /Plasmid Origin 
HPV18E7 entire HPV18-Genome/pRB322 Boshart et al., 1984 
β-Actin nearly complete β-Actin-gen/pHFA1  
Gunning et al., 1983; obtained 
from Dr. L. Kedes (Medical 
Center, Palo Alto, USA) 
 
 
2.1.9 Size markers for DNA /RNA electrophoresis 
 
DNA Analysis:       Company: 
• 1Kb plus DNA Ladder      cat# 10488-085   Invitrogen 
• 100 bp DNA Ladder        cat# 10488-058  Invitrogen 
RNA Analysis:  
The ribosomal RNA (28S, 18S, 5,85S and 5S bands), which was visible in ethidium bromide 
stained gels was used as a standard. 
28 S    4718 bp 
18S    1874 bp 
5,85S    160 bp 
5S    120 bp   (in eukaryonts) 
 
2.1.10 Kits 
 
Absolutely RNATM RT-PCR Miniprep Kit   Stratagene 
EffecteneTM transfection Reagent    Qiagen, Hilden 
PolyfectamineTM Transfection Kit    Qiagen, Hilden 
Hexalabel PlusTM DNA Labeling Kit   MBI Fermentas, Vilnius 
High Sensitivity β-galactosidase Assay Kit   Stratagene 
One-Shot® TOP10      Invitrogen 
Plasmid Purification Kit     Qiagen, Hilden 
Qiaquick Gel Extraction Kit     Qiagen, Hilden 
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2.1.11 Others 
 
Autoradiography cassettes (Kodak)    Sigma, Deisenhofen 
Cell culture flasks      Costar  
Cell culture plates      Greiner, Nürtingen 
Cryo-tubes       Greiner, Nürtingen 
Eppendorf Tubes      Eppendorf, Hamburg 
Films (HyperfilmTMECL)     Amersham-Pharmacia, Freiburg 
Glass pipettes       Renner, Darmstadt 
Glass wool       Serva, Heidelberg 
Nylon membranes (GeneScreen PlusTM)   NEN Lifescience Products Inc 
Paperfilters       Schleicher and Schüll, Dassel 
Pipet Tips (Sterile)      Becton and Dickinson, Heidelberg 
Pipet Tips       Greiner, Nürtingen 
Photometer plastic Cuvettes     Greiner, Nürttingen 
Polypropilene conical tubes     Falcon, Becton-Dickinson 
PVDF-membranes (Immobilon P)    Millipore, Eschborn 
Sterile filters       Millipore, Eschborn 
X-ray films        Fuji 
Whatmann 3MM paper filter     Schleicher and Schüll, Dassel 
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2.2 METHODS 
 
2.2.1 Cell culture techniques 
2.2.1.1 Cell culture 
Cervical carcinoma cell line HeLa, SW756, human fibroblast and HeLa hybrid cells 444 and 
CGL-3, and the stably transfected TE-671 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10 % FCS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. 
The E6- and E7- immortalised keratinocytes were sustained in Keratinoycte Growth Medium 
(Serum –Free Keratinocyte Medium supplemented with Bovine Pituitary Extract (BPE; 20-30 
µg/ml). 
In order to keep the selection pressure the clones were grown in a media containing 750 µg/ml to 
1 mg/ml G418. The concentration of G418 was increased to achieve a better selection. 
Incubation was carried out at 37°C with 5% CO2 and 95% humidity. Cell cultures that reached 
sub-confluent growth (80-90% confluence) were washed once with PBS and treated with 
Trypsin/EDTA at 37°C until the cells detached from the plate. The trypsinization was stopped by 
the addition of complete DMEM and the cells were splitted between 1/5 and 1/30. 
 
2.2.1.2 Thawing and freezing of eukaryotic cells 
For thawing, the cryo-vials were warmed up to 37°C, once unfrozen the cell-containing medium 
was transfer to a 15 ml falcon tube and diluted with DMEM complete medium in the ratio of 
1:10. The cells were sedimented by centrifugation at 2000 rpm and 4°C, for 5 min (Varifuge RF, 
Heraus). Then the pellet was resuspended in fresh medium and transferred to a culture flask or 
plate for incubation at 37°C with 5% CO2 and 95% humidity. 
For freezing sub-confluent culture plates (80-90% confluence) were trypsinized as mentioned in 
2.3.1.1. The cells were centrifuged for 5 min at 2000 rpm (Varifuge RF, Heraus), 4°C and the 
pellet was resuspended in freezing medium. The cell suspension was transferred to cryo-vials (~ 
1ml = 106cells/ml/vial) and cooled down to -70°C. Later the cryo-vials were transferred to a 
storage tank with liquid nitrogen for long term conservation. 
 
2.2.1.3 Cell Counting 
In order to determine the cell concentration (cells/ml), trypan blue staining was used which 
allows visualising of living cells. After trypsinization the cell suspension was transferred to a 15 
ml blue tube (Falcon). A certain volume of cell suspension was mixed with trypan blue dye 
solution in a ratio of 1:1. Living cells were counted in a Neubauer chamber. 
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The number of cells was calculated as follows: 
 
Cells / ml = number of cells counted x 10 4 x Dilution factor 
                  Number of squares counted 
 
2.2.1.4 Cell treatment with Sodium Butyrate, MG-132, TLCK 
i) Confluent cells were treated with 6 mM SB (0,66 mg/ml) dissolved in DMEM for 16 or 24 h. 
The solution was always prepared fresh. 
ii) Confluent cells were treated with 50 µM, 100 µM, 125 µM and 250 µM TLCK for 16 hours 
with or without SB. The stock solution for TLCK was prepared as 50 mM dissolved in bi-
distilated water. The control treatment was implemented using DMEM. 
iii) Confluent cells were treated with 2 µM of MG132 for 16 h. The stock solution was prepared 
at 20 mM and stored at -20°C. The final concentration of the solvent DMSO in the culture media 
was 0.1% (v/v). The control cultures received media containing 0.1% (v/v) DMSO alone and 
were incubated under the corresponding conditions. 
 
2.2.2 Preparation of DNA probes  
2.2.2.1 Transformation of Competent bacteria (Dagert and Ehrlich, 1979) 
Commercially available One-shot® TOP 10 competent cells were thawn on ice, 2 ng of DNA 
were added, mixed and incubated for 30 minutes on ice. Later the cells were incubated at 42°C 
for 30 seconds and then chilled on ice for 2 minutes. The cells were diluted 1:5 in pre-warmed 
SOC-Medium and incubated for 1 hr at 37 °C under constant shaking. Twenty and two hundred 
microliters of the transformed cells were plated on LB-ampicillin plates and incubated at 37°C 
overnight. Next day, an individual colony was picked, transferred to 10 ml ampicillin-containing 
LB-medium and incubated for about 8 h at 37°C.  
 
2.2.2.2 Plasmid-DNA restriction analysis  
See section 2.3.4.3 DNA restriction analysis and 2.3.4.4 DNA electrophoresis and Southern blot. 
2.2.2.3 DNA extraction from agarose gel (QIAquick gel ectraction kit) 
DNA fragments were extracted from agarose gels using the QIAquick gel extraction kit 
(Qiagen). The protocol allows the extraction of DNA fragments in size ranges between 100 bp to 
10 Kbp. After agarose gel electrophoresis the DNA fragment was cut out from the gel, 
transferred into an eppendorf tube and treated (subsequently) as described in the attached 
instruction manual. 
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2.2.3. Protein analysis  
2.2.3.1 Preparation of nuclear and cytoplasmic proteins (Schreiber et al., 1989) 
Nuclear extracts were prepared using the method of Schreiber et al. with the only modification 
that phosphatase inhibitors and protease inhibitors were included in the buffers A and C at 
concentrations suggested by the manufacturer. 
 
Stock:     Activity:   Final concentration: 
0.1 M DTT        1 mM 
23.8 mg/ml (in H2O) Pefabloc SC Serine proteases inhibitor 0.5 mg/ml 
2.5 µg/ml (in H2O) E-64  Cysteine-protease inhibitor 5 µg/ml 
0.5 M NaF    Phosphatase inhibitor  1 mM 
10 mM Na3VO4   Phosphatase inhibitor  0.2 mM 
 
For the nuclear-cytoplasm protein extraction a 60 cm2-culture plate with 90-100% confluence 
(app. 3x106 cells) was washed twice with isotonic PBS. Then 1.6 ml of the hypotonic buffer A 
was added and the cells were scrapped. The cell suspension was placed into an eppendorf tube 
and cooled on ice for 15min to allow swelling of the cells. Subsequently, 100 µl of a 10% 
Nonidet P-40 solution, a non-ionic detergent were added to the cell suspension and the eppendorf 
tube was vortexed for 10sec for plasma membrane lysis. After centrifugation at 14.000 rpm, 1 
min., 4°C the supernatant contains the cytoplasmic proteins and the pellet the intact nuclei, 
which kept the nuclear proteins inside. 
The cytoplasm protein-containing extract was aliquoted and stored at -70°C. In this extracts the 
protein concentration was determined by the Biorad DC (Detergent Compatible) protein assay 
based on a modified Lowry method (Lowry, 1951). For each sample 2-4 µl of cytoplasmic 
protein extract was diluted in 200 µl of bi-distilated water, next 100 µl of the reagent A* (1ml 
Reagent A plus 20 µl Reagent C) and 800 µl of Reagent B were added, mixed and incubated for 
15min at room temperature. Finally, the absorbance of the samples was measured 
photometrically at 750 nm and the concentration was determined using a standard BSA curve as 
reference. 
The nuclei-containing pellet was resuspended in 200 µl of ice cold buffer C and placed on ice for 
15 min mixing it every 2 min. Finally, the extract was centrifuged at 14.000 rpm, 5 min, 4°C and 
the nuclear protein containing-supernatant was aliquoted and stored at- 70°C. The protein 
concentration of the nuclear extracts was determined by Bio-Rad Bradford-Method (Bradford, 
1976). Two to five µl of the nuclear protein preparation were diluted in 800 µl of bi-destilated 
water and 200µl of the Biorad reagent was added. After gentle mixing the absorbance was 
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measured at 595 nm and the protein concentration was determined using defined amounts of 
BSA as standard. 
 
2.2.3.2 SDS-total protein extracts (Harlow and Lane, 1988) 
To prepare protein extracts, cells were washed twice with cold PBS and were lysed with 500 µl 
of RIPA buffer supplemented with freshly added proteases inhibitor cocktail (Complete™). The 
lysates were scrapped and transferred to an eppendorf tube. Afterwards, the lysates were sonified 
three times for 15 sec (50% power capacity, position 5) at 4°C and incubated for 30 min on ice. 
Following centrifugation for 5 min at 14000 rpm and at 4°C, the supernatant was divided in 200 
µl aliquots and stored at -70°C. Protein concentration was determined by the Bradford method 
(Bradford, 1976). 2 µl of cell extract were diluted in 798 µl of bidistilated water, and 200 µl of 
the Bio-Rad reagent were added, mixed gently and quantified at 595 nm. The concentration was 
determined automatically by the spectrophotometer using BSA as reference.  
 
2.2.3.3 SDS-Polyacrylamide gel electrophoresis (Laemmli, 1970; Hames and Rickwood, 
1990) 
This system is based on a discontinuous gel in which the stacking and separating gel layers differ 
in salt concentration, pH and acrylamide concentration. Depending on the size of the protein 8% 
to 15% acrylamide gels were used, the separating gel contains 0.4M Tris pH 8.8, 0.1%SDS, 8-15 
% Acrylamide/Bis-acrylamide (29:1), 0.5% ammonium persulfate and 0.07% TEMED. After 1 h 
of polymerisation at room temperature, a 3% stacking gel solution was added, the stacking gel 
contains 0.125M Tris pH 6.8, 0.1% SDS, 3% Acrylamide/Bis-acrylamide (29:1), 0.5% 
ammonium persulfate and 0.16% TEMED. Between 25-50 µg of total protein were mixed with 
2x Western loading buffer, heated at 95°C for 5 Min and loaded on the gel. The run was 
performed in 1x Laemmli’s running buffer and the running time was approximately 2 h (15 mA 
until dye front reached separating gel, then 30 mA). 
 
2.2.3.4   Western Blot ”Semidry” (Gallagher et al., 1997) 
The proteins were transferred from the gel to polyvinylidene fluoride PVDF-membranes using a 
semidry blotting system. After electrophoresis the transfer stack was assembled: on the semidry 
blotter 9 sheets of whatman 3MM filter paper were placed cut to the gel dimensions and soaked 
with 1x Towbin buffer, followed by the pre-activated membrane and on top of the gel another 9 
sheets of whatman 3MM paper soaked with Towbin buffer . The transfer proceeded at 0.8-1.2 
mA/cm2 at 4°C for 70 min, depending on the protein size. 
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Then PVDF-membrane was incubated for 1hour at room temperature in blocking solution, and 
subsequently incubated overnight at 4°C with the first antibody (diluted in blocking solution or 
BSA following the manufacturer recommendations). Next day, the membrane was washed five 
times with TBST 5 min each, followed by the incubation with the secondary antibody in 
blocking solution for 1h at room temperature. Finally, the membrane was washed again as 
described before, incubated for 2 min with ECL reagent and exposed to HyperfilmTM ECL films. 
In order to use the same membrane for incubation with additional antibodies, membranes were 
“stripped” in 200mM NaOH for 5 min and washed with water and TBS. Then they were ready 
for blocking and further antibody incubation. 
 
2.2.4 Nucleic acid analysis 
2.2.4.1 RNA extraction (Absolutely RNA™ RT-PCR Miniprep kit) 
RNA was isolated with the Absolutely RNATM RT-PCR miniprep kit (Stratagene) according to 
manufacturer’s instructions. For the RNA extraction a 60 cm2-culture plate with 90-100% 
confluence (appr.3x106 cells) was washed twice with isotonic PBS, 500µl of PBS were added 
and the cells were scrapped and transferred to an eppendorf tube. Cells were sedimented at 3000 
rpm (Varifuge RF, Heraus), room temperature, 5 min. The cell pellets were re-suspended in 600 
µl of Lysis buffer supplemented with 4.2 µl of 2-mercaptoethanol and vortexed repeatedly to 
ensure that the viscosity of the lysate was low. Afterwards, the lysate was filtered and mixed 
with 70% DEPC-ethanol. The filtrate was transferred to a Fiber-Matrix Spin Cup in order to 
allow the binding of the nucleic acids to the matrix. The matrix was washed once with low salt 
washing buffer and then the DNase treatment was proceded. Next, the matrix was washed once 
with high salt buffer and twice with low salt buffer and the pure RNA was eluted from the matrix 
with TE pH 7.5 at 60°C. The concentration of the RNA was determined photometrically by 
measuring the optical density (OD) at 260/280 nm. 1 OD unit corresponds to 40 mg RNA/ml. 
To check RNA quality, 5 µg of RNA were separated on a 1% agarose /1X MOPS gel in the 
presence of ethidium bromide under non-denaturating conditions (section 2.2.4.5.) 
 
2.2.4.2 DNA extraction from eukaryotic cells 
Cells were washed twice with PBS, incubated with 3 ml ”DNA lysis buffer” for 10 min at room 
temperature, scrapped and transferred into 15 ml falcon tubes. Proteinase K was added to a final 
concentration of 200 ng/ml and incubated at 56°C for 1 hour. Nucleic acid was purified using 
phenol/ chloroform extraction. After centrifugation, the upper DNA-containing aqueous phase 
was transferred into a new tube where DNA was precipitated after addition of ammonium acetate 
(2 M final concentration) and 0.8 volumes of isopropanol. The mixture was centrifuge and the 
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pellet was washed twice with 70% ethanol, air-dried and resuspended in TE buffer. The 
concentration of DNA was determined photometrically by measuring the optical density (OD) at 
260/280 nm. 1 OD unit corresponds to 50 mg DNA/ml. DNA was treated with RNAse A 
(Ribonuclease A, 10µg/ml) for 10 minutes at 37 °C. 
 
2.2.4.3 DNA restriction analysis 
For restriction analysis, 1 µg of DNA was supplemented with 2U of restriction enzyme with the 
corresponding buffer as recommended by the manufacturer. After 2 hours at 37°C, DNA was 
loaded on agarose gels. 
  
2.2.4.4 DNA electrophoresis and Southern Blot 
Agarose gel electrophoresis is a standard method to separate, identify and purify nucleic acid 
fragments. The concentration of the agarose used for the gel depends on the size of the DNA 
fragments to be analysed. By using the fluorescent intercalating dye ethidium bromide at a final 
concentration of 0.5 µg/ml, the visualization of the nucleic acids within the gel is possible.  
The required amount of agarose was added to the appropriate amount of 1X TAE buffer and the 
mixture was heated to allow the agarose to dissolve. The solution was cooled down and ethidium 
bromide was added to a final concentration of 0.5 µg/ml. The gel was poured and allowed to 
solidify. The gel was transferred to an electrophoresis chamber filled with TAE 1X buffer and 
the samples were loaded after being mixed with agarose loading buffer (6:1). The electrophoresis 
proceeded between 2-8 V/cm. Later the gel was place on an UV transilluminator and 
photographed. 
After DNA restriction and electrophoresis, the agarose/1X TAE gel was incubated for 45 min in 
denaturing solution. 
For blotting, a pack of high absorbent paper was used and 4 pieces of 3MM paper were placed 
on it (first 2 papers dry and then 2 papers wet after soaking in non-denaturing solution). Gene 
Screen nylon membrane, previously incubated for 1min in bidistilated water and 15 min in 
denaturing–solution, was placed in the 3MM wet paper. Finally, the agarose gel was laid on the 
nylon membrane (see Figure 2.1). The whole assembly was then covered with plastic paper and 
left overnight at room temperature. Next day, the nylon membrane was washed for 15 min in 
neutralization solution and air-dried over 3MM paper. The membrane was then ready for 
hybridization.  
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2.2.4.5 RNA electrophoresis and Northern Blot (Alwine et al., 1977) 
RNA was separated in 1% agarose/ 1X MOPS/ ethidium bromide gels under non-denaturing 
conditions. One volume of RNA-loading buffer was added to each probe, heated 10 min at 65°C 
and cooled on ice for 3 min before loading. The gel was run at 60 V for 2 h and then 
photographed. 
After electrophoresis the gel was incubated for 15 min in 20X SSC buffer. For blotting, a pack of 
high absorbent paper was used and 4 pieces 3MM paper were placed on it (first 2 papers dry and 
then 2 papers wet by soaking in 20X SSC buffer). Gene Screen nylon membrane previously 
incubated for 1 min in bi-distilated water and 15min in 20X SSC was laid on the 3MM paper. 
Finally, the gel was deposited over the nylon membrane and the whole assembly was wrapped 
with plastic paper (see also Figure-2.1). RNA transfer proceeded over night at room temperature. 
Next day, the nylon membrane was washed for 5 min in 2X SSC and air-dried over 3MM paper. 
After this step, the membrane was ready for hybridization. 
 
2.2.4.6 Probe labelling, “Random Priming” (Feinberg and Vogelstein, 1983) and 
hybridization (Southern, 1975) 
The radioactive probes for hybridization analysis were obtained by random priming, in which a 
mixture of random hexamers is used to prime DNA synthesis in vitro from a linear denaturated 
DNA template. For this purpose the “HexalabelTM DNA labelling kit” was used. Briefly, 100ng 
DNA were diluted in 1X reaction buffer, boiled 10min and cooled down on ice. Later, the 
appropriated nucleotides mix (-dCTP), 25 µCi/µl α32P-dCTP and 5U of Klenow-polymerase 
were added. The reaction was incubated for 30 min at 37°C, then a complete dNTP mix was 
added and the incubation was prolonged 5 min. Subsequently, the unincorporated label was 
removed by filtration of the TNE-diluted labelling reaction through a Biogel-suspension column. 
Blot pre-hybridization was performed in hybridization buffer for at least 1 h at 42°C, after that 
denaturated radioactive probe was added to the pre-hybridized membrane and hybridization 
proceeded over night. Next day, filters were washed two to three times depending on the 
radioactive signal, with hybridization washing buffer at 68°C and exposed on Hyperfilm™ ECL 
films at -70°C.  
 
2.2.4.7 Reverse transcription and Polymerase Chain Reaction (PCR): Semi-quantitative 
            RT-PCR  
cDNA was obtained from one to five micrograms of RNA by using oligo(dT)22 or gene specific 
primers (as template-primer) and SuperScript II reverse transcriptase following the 
manufacturer’s instructions. The Oligo(dT)22 (500µg/ml) or gene-specific primer (GSP) (2 
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pmol) and the RNA were heated at 70°C for 10 min. and chilled on ice. Then the mixture was 
supplemented with 1X reverse transcription (RT) buffer (50mM Tris-HCL pH 8.3, 75mM KCl, 
3mM MgCl2), 10mM DTT, 500µM dNTPs and incubated at 42 °C for 2 min for the annealing 
step. After annealing, 100 U of reverse transcriptase SuperScript II were added and the reaction 
was incubated for 50 min at 42°C for the cDNA first-strand synthesis. Finally, the cDNA was 
heated to 70°C for 15 min and chilled on ice. 
RT–PCR reactions were prepared with the Oligo(dT)22 primer in order to analyse the 
transcriptional level of pRb, GAPDH and p73 in HeLa cells while the reverse primer sequence 
from the p73 (Sayan et al., 2001) was deployed as a gene-specific primer (GSP) for the RT 
reaction in E6 and E7 keratinocytes in order to analyse the p73 trancription. 
PCRs were performed in 50µl final volume containing 10mM Tris-HCl pH 8.3, 200µM dNTPs 
mix, 500nM of each primer, 50mM MgCl2, 5U of Taq platinum polymerase and 1-5 µl of cDNA. 
Except of some individual cases all PCR reactions were performed for 35 cycles consisting of 
the following steps: 
1. Step: Denaturation at 95°C for 5 min. 
2. Step: Denaturation at 95°C for 30-45 sec. 
3. Step: Annealing with corresponding temperature for 30 sec (1 min. for p73 PCR with the 
primers from Rainer Schmidt) 
4. Step: Extension at 72°C for 1min (2 min. for p73 PCR with the primers from Rainer Schmidt) 
5. Step: repeat of the steps from 2 to 4 for 34 times 
6. Step: Final extension at 72°C for 10 min.  
The amount of cDNA and the number of cycles were carefully standardized in order to reach a 
semi-quantitative indication of the RNA content. The PCR products were analysed in 0,5-2% 
agarose gels. 
Notably, for the transcriptional analysis of p73 two different primer pair was used. Thus for 
HeLa cells the primers designed from Rainer Schmidt, while for the E6 and E7 keratinocytes the 
primer sequences from Emre Sayan (MRC Toxicology Unit, University of Leicester, UK) 
(Sayan et al., 2001) were applied.  
 
2.2.5 Transfection analysis 
2.2.5.1 Stable transfection protocol “Effectene” 
The stable transfections of the TE-671 cells (section 3.2) were done according to the Effectene 
protocol. Thus 2.5x106 cells were plated in 60-cm2 dishes the day before transfection. Next day, 
2µg of the plasmid DNA (pcDNA3.1/16E7-Kozak and pcDNA3.1/(-)) were mixed with 300 µl 
of DNA-condensation buffer, 16µl of enhancer and 60µl of effectene, following the incubation 
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time recommended to allow the complexes formation, 3 ml of complete DMEM were added and 
the transfection complexes were poured onto the cells. Cells were incubated overnight in the 
presence of the pDNA-transfection-complexes. Next day cells were washed with PBS and new 
DMEM medium was added. After the cells started to grow exponentially, DMEM medium was 
supplemented with the selection marker Geneticin (G418). The final concentration of the 
selection marker was 1mg/ml. Approximately 3 months after transfection cells were plated on 
96-well plates to select single clone cells. Approx. after 6 months single cell clones, which were 
growing exponentially were plated on 60 cm2 dishes later on 100- cm2. In order to check the 
presence of the introduced plasmid protein western blot analysis was performed. 
The transfection efficiency in TE-671 cells was higher than 30% as determined by transfection 
with expression vector carrying the enhanced green fluorescence protein (EGFP). 
  
2.2.5.2 Transient transfection by Calcium-Phosphate co-Precipitation (Chen and Okayama, 
1987). 
In this transfection protocol, calcium phosphate forms complexes with DNA gradually in the 
medium during incubation with cells and precipitates on the cells. The crucial factors for 
obtaining efficient transformation are the pH (6.95) of the buffer used for the calcium phosphate 
precipitation, the CO2 level (3%) during the incubation of the DNA with the cells, and the 
amount (20 to 30 micrograms) and the form (circular) of DNA.  
Thus, for the experiment in section 3.2 confluent grown HeLa cells were transiently transfected 
in 100-cm2 Petri dishes with 20 µg of the respective pSUPER-derived vector constructs. For 
each transfection the following mixture was prepared: 
420µl H2O were mixed with 20µg of the corresponding plasmid DNA. After addition of 500µl 
2X HBS were mixed again. Immediately after adding 62µl of 2M CaCl2 the samples were 
vortexed vigorously. The final volume of 1ml was added to the cell medium. After incubation at 
room temperature for 30 min the solution was mixed gently by pipetting up and down. The 
mixture was added to the cells dropwise. 
After 12 hours cells were washed once and incubated for additional 24 hours in supplemented 
DMEM medium. Afterwards, cells were treated with 6 mM SB for 24 hours or the medium was 
changed. Finally, cells were harvested for protein and for RNA extraction (Figure-19 A and B). 
As control, HeLa cells were transfected with pSUPER-vector alone and pSUPER-vector 
expressing luciferase gene which should not interfere with any mammalian transcript. 
The transfection efficiency in HeLa cells was higher than 80% as determined by transfection 
with expression vector carrying the enhanced green fluorescence protein. 
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2.2.6 DNA staining with DAPI and SR 101 for flow cytometry and cell cycle analysis    
As indicated in section 3.5 and 3.6 cells were analysed for their cell cycle distribution and for 
their sub-G1 fraction. Therefore 4x104 cells per 60-cm2 dish were seeded. After incubation for 
the corresponding treatment, the old DMEM medium (5 ml) has been transferred in a 15ml 
falcon tube. Cells were washed with 3 ml 1x PBS and this part was also added to the collection 
tube. Afterwards, cells were harvested with 2ml trypsin. The trypsinated cells were also added 
into the same tube. Cells were gently centrifuged at 1500 rpm for 5min. Next cells were washed 
three times with 1x PBS. Finally, cells were resuspended in 1ml 1x PBS and were fixed with 
ethanol (above 75%) for a minimum of 12 hours.  
After mild centrifugation at 100 g for 15 min. the cell pellet was resuspended in a fluorochrome 
mixture of TRIS buffer (0.18M, pH 7.5) containing DAPI (Diamidinophenylindole from Serva 
5x10-6 M) for DNA staining and SR 101 (sulforhodamine 101 from Eastman Kodak, 5x10-5 M) 
as a protein counter stain, exactly following a protocol published by Stoehr et al. (1978). Flow 
cytometry was performed using the UV lines of an argon ion laser to excite both the blue and red 
fluorescence of DAPI and SR101, respectively, which could easily be separated by simple 
optical filtering. Blue fluorescence of DAPI has been collected above 450 nm. Analysis of the 
cellular DNA frequency distributions for apoptosis and cell cycle distribution was carried out 
with computer assistance according to Dean and Jett (1974) and Stoehr et al. (1976 and 1991).  
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III. RESULTS  
 
3.1 Analysis of HPV- positive cell lines after HDAC inhibition  
3.1.1 HDAC inhibitors induce pRb degradation only in the presence of HPV oncogenes  
 
To analyse the degradation of pRb protein in the presence of viral E7 oncoprotein following 
administration of HDAC inhibitors (HDACi), HPV18 transformed HeLa cells were initially 
used. For preliminary analysis, HDAC inhibitor concentrations of SB (6 mM) and TSA (330 
nM) were chosen. The cells were treated for 24 hours and total protein extracts were prepared. 
Figure-3.1 A, shows pRb degradation upon HDAC inhibition while the level of E7 oncoprotein 
was not affected by SB. To determine whether HDACi induced pRb degradation was cell line 
specific, another HPV18 positive cell line was tested. SW756 is a cervical cancer cell line 
containing 10-to 50 copies of HPV18 DNA integrated at a single site on chromosome 12 
(Schwarz et al., 1985; Popescu et al.,1987a and b; Mincheva et al., 1987). Figure-3.1 B also 
demonstrates pRb degradation at the same HDAC inhibition conditions previously used for 
HeLa cells. However, the expression levels of E7 were moderately affected.  
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Figure-3.1: Treatment of HPV 18 positive HeLa and SW756 cells with HDAC Inhibitors SB and TSA induce 
pRb degradation 
Western Blot analysis of cellular extracts obtained from (A) HeLa and (B) SW756 cells. Proteins were separated in 
8% (pRb) and 12% SDS-PAGE. After electrotransfer, the filters were incubated with anti- pRb, HPV18E7. Control: 
untreated cells, DMSO: Cells treated with 0.1 % DMSO. Treatments for SB (6 mM) and TSA (330 nM) were done 
for 24 h. The protein loading was confirmed by using anti-actin antibody. 
 
The multiple bands of pRb represent different phosphorylation states of the protein. In HeLa 
cells, only TSA down-regulated E7 protein levels, whilst in SW756 only a moderate repression 
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of the oncogene was visible. This might be due to the fact that TSA is an HDAC inhibitor with a 
broader spectrum than SB (Marks et al., 2001). 
 
These first results, suggested there were two potential perspectives of how the observed 
degradation of pRb may occur: One possibility is the tumorigenic phenotype and secondly the 
presence of the viral oncogene E7. To discriminate between these two options, the HPV negative 
cervical cancer cells C33-A and HT-3 (Heilman et al., 1980) were analysed. 
As demonstrated in Figure-3.2, HDAC inhibition SB and TSA resulted in an unaltered level of 
pRb protein. Notably, in each of the HPV-negative cell lines, HDAC inhibitors only altered pRb 
mobility. The faster migrating form of pRb, appeared as a 97 kDa band in both cell lines, 
indicates the presence of the hypophosphorylated form of pRb. In the case of HT-3 cells, levels 
of hyperphosphorylated forms of pRb protein could also be detected as described by Scheffner et 
al., 1991.  
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Figure-3.2: Immunoblot Analysis of HPV negative cells, C33-A and HT-3 
Analysis of pRb in C33-A (A) and HT-3 cells (B). 75 µg of cellular extracts were separated on a 8% SDS-PAGE gel 
(pRb). After electrotransfer, the filters were incubated with anti-pRb and anti-actin antibodies. Control: untreated 
cells, DMSO: Cells treated with 0,1% DMSO. Treatments for SB and TSA were done for 24 h. Position of the pRb 
protein in hypophosphorylated (indicated here as pRb) or hyperphosphorylated (ppRb) forms. 
 
From these results one can conclude that the presence of viral oncogenes, especially E7, is 
obviously a prerequisite for the observed pRb degradation in the presence of HDAC inhibitors. 
To prove this hypothesis and to exclude that the tumorigenic phenotype is a critical determinant, 
somatic cell hybrids were used (Stanbridge et al., 1976). This system is based on cell fusion 
between HeLa and non-tumorigenic fibroblast, resulting in non-tumorigenic cells (444). Long 
term in vitro propagation results in tumorigenic segregants (CGL-3). 
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The advantage of this model system is that these cells retain the integration and transcription 
pattern of HPV18 sequences of the parental HeLa cells whilst their in vivo properties are 
different. Inoculation of CGL-3 cells into athymic nude mice leads to a formation of progressive 
tumors, while “444” cells do not (Stanbridge et al., 1982) and are therefore considered to be non-
tumorigenic. 
‘444’ and the ‘CGL-3’ cells were treated with 6 mM SB or with 330 nM TSA for 24 hours. 
Figure-3.3 shows that, similar to HeLa cells, pRb was degraded. Hence, pRb degradation upon 
SB and TSA was occurred independent from the in vivo phenotype.  
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Figure-3.3: Treatment of somatic cell hybrids with HDAC Inhibitors  
Western Blot analysis of cellular extracts (75 µg) obtained from (A) 444, (B) CGL3 cells after 24 h treatment. Total 
protein lysates were separated on 8% (pRb) or 12% (HPVE7) SDS-PAGE gels. After electrotransfer, the membranes 
were incubated with anti- pRb, HPV18E7 and anti-actin antibodies. Control: untreated cells, DMSO: Cells treated 
with 0.1 % DMSO. SB: (6 mM), TSA: (330 nM)  
 
In summary, these data show that apparently the presence of the viral oncogenes is the major 
determinant for pRb degradation. 
 
3.1.2 HPVE7 is selectively responsible for the degradation of pRb in the presence of HDAC 
inhibitors 
 
In order to analyse which of the two viral oncogenes is responsible for the pRb degradation upon 
HDAC inhibition, human keratinocytes were used, which were individually immortalised with 
amphotropic retroviruses carrying either HPV16E6- or E7 (Aguilar-Lemarroy et al., 2002). 
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As demonstrated in Figure-3.4 A by Westernblot analysis, only E7 immortalised keratinocytes 
showed pRb degradation with SB and TSA, whereas in E6 immortalised cells, a 
hypophosphorylated form of pRb can be detected (Figure-3.4 B). This result suggests that pRb 
degradation is dependent on the presence of E7.  
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Figure-3.4: Western Blot analysis of pRb and viral proteins of (A) E7-, (B) E6- immortalised keratinocytes 
after SB and TSA treatment. 
Western Blot analysis of cellular extracts obtained from (A) E7- and (B), E6-immortalised keratinocytes were 
separated on 8% (pRb) and 12% (E7) SDS-PAGE. After electrotransfer, the membranes were incubated with anti- 
pRb, and with anti-HPV16-E7 antibodies. Equal protein loading was confirmed by incubation of the membranes 
with an anti-actin antibody. Control: untreated cells, DMSO: Cells treated with 0.1 % DMSO, SB (6 mM), and TSA 
(330 nM). Treatments were done for 16 h. 
 
3.1.3 Degradation releases negatively regulated target genes from pRb suppression  
 
One of the main functions of pRb is the transcriptional regulation of genes involved in the G1 to 
S phase transition such as cyclin E, DNA polymerase-α, dihydrofolate reductase (DHFR), 
thymidine kinase (TK) (Weinberg et al., 1995b; Muller et al., 2001). The pRb protein is able to 
repress the transcription of the cell cycle regulatory proteins by binding to E2F, a transcription 
factor playing the major role during cell cycle progression and by recruiting the HDAC1 
molecules to their promoters (Brehm et al., 1998; Harbour and Dean 2000a; Zhang and Dean, 
2001). Therefore one might predict that a decrease in pRb levels could lead to increased release 
of E2F, which in turn can bind to target sequences in the respective genes and induce their 
transcription. Indeed, in tumorigenic HPV positive cells and keratinocytes expressing either E6 
or E7, a clear increase of cyclin E expression was observed (Figure-3.5A). The E2F levels 
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Actin
E2F
remained unaffected in HPV positive cells and in E7 keratinocytes while a slight downregulation 
was observed in E6 keratinocytes (Figure-3.5 B). 
Nevertheless, these results indicate that degradation of pRb was accompanied by an increased 
expression of genes, negatively regulated by pRb. 
 
Figure-3.5: Enhanced 
degradation of pRb upon 
HDAC inhibition activates 
E2F: Upregulation of cyclin 
E expression in HPV18 
positive cells and in 
immortalised E6- and E7 
keratinocytes 
Western Blot analysis of 
cellular extracts (75 µg) 
obtained from HeLa, SW756, 
444 and CGL-3 cells and from 
HPV16E7- or E6 immortalised 
keratinocytes. Total protein 
lysates were separated on 12% 
SDS-PAGE. 
 After electrotransfer, the 
membranes were incubated 
with anti-cyclin E (A) and 
anti-E2F (The upper band 
corresponds to the 60 kDa E2F 
protein) (B). For loading 
control same membranes were 
incubated with anti-actin 
antibodies. Control: untreated 
cells, DMSO: Cells treated 
with 0.1 % DMSO. Treatments 
for SB (6 mM) or TSA (330 
nM) were applied for 24 h 
(HeLa, SW756, 444, CGL-3) 
and for 16 h (E7- and E6 
keratinocytes) 
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3.2 The role of HPV E7 in pRb degradation by SB  
 
Based on the previous results, a functional link between pRb degradation after HDAC inhibition 
and the presence of HPVE7 oncoprotein was predicted. 
Therefore, the following experimental strategy was carried out (Figure-3.6): 
a) Monitoring the effect of HDAC inhibitors on pRb in HeLa cells following HPV18-E7 knock 
down by siRNA.  
b) Ectopic expression of HPV16-E7 in HPV negative, but pRb positive Rhabdomyosarcoma 
cells (TE-671). 
 
 
HPV(+)
pRb (+)
Knock-down of HPV18-E7 
by specific siRNA in HeLa
HPV(-)
pRb (+)
Introduction of HPVE7 into
TE671 cells by a HPV16-E7 
expression vector
Effect of E7 depletion on 
HDACi induced pRb
degradation
Is delivery of E7 sufficient to 
sensitize cells to HDACi
induced pRb degradation ?
??
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3.6: Scheme of the experimental strategy to study the role of HPV in HDAC inhibitor SB induced pRb 
degradation. 
 
To test the first strategy in HeLa cells, a pSUPER vector containing a specific siRNA (19 nt, 
Figure-3.7 b) designed for the knock down of E7 transcripts (Figure-3.7 a) (Kuner et al., 2007) 
was used. The Figure-3.7 c shows its predicted secondary structure.  
Exponentially growing HeLa cells were transfected with pSUPER-18E6/E7 while controls were 
transfected with empty pSUPER- or pSUPER-luciferase vector. After 48 h of transfection, cells 
were treated with 6 mM SB for 24 hours. Northern blot analysis was performed to monitor the 
specific transcriptional downregulation of E7. As seen in Figure-3.8 A (lanes 4 and 8), a marked 
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reduction of HPV transcripts was detected, while control transfected cells were not affected. The 
equal loading and RNA quality was monitored by ethidium bromide staining of the ribosomal                              
RNAs 28S (4,9 Kb) and 18S (1,9 Kb). Transcriptional suppression of E7 oncogene was also 
analysed on protein level (Figure-3.8 B), where the amount of E7 was reduced after specific 
siRNA expression. 
 
Figure-3.7: Schematic presentation 
of the HPV18 siRNA plasmids 
(Vogt et al., 2007)  
(a) Schematic overview of the 
HPV18 transcripts in HeLa cells,. The 
sequence targeted by pSUPER-18-
E6/E7 is schematically indicated by 
bold red colour line for pSUPER-
18(3-5). (b) The target sequence of 
pSUPER18 E6/E7 (19 nt). Synthetic 
double stranded oligonucleotide 
derived from the HPV18-E7 gene was 
cloned into pSUPER vector resulting 
in pSUPER-18E6/E7 construct. 
b)
18E7(3-5)(755-773): 5‘-CCACAACGTCACACAATGT-3‘
c) 5‘-CCACAACGTCACACAATGT-
: : : : : : : : :: : : : : : : : : :
3‘-UU-GGUGUUGCAGUGUGUUACA-
U
U C A
A
A A
G
G
(c) Predicted secondary structure of 
the RNA encoded by pSUPER-
18E6/E7-(3-5) (Kindly obtained from 
Felix-Hoppe -Seyler). 
 
Previous results demonstrated that HDAC inhibitor induced degradation of pRb was due to 
posttranslational events, because the steady state level of pRb mRNA was maintained upon 
treatments with HDAC inhibitor SB (Finzer et al., 2001). Here, it was analysed whether 
transcription of pRb was influenced directly by downregulation of HPVE7 or whether siRNA per 
se could downregulate pRb transcription. Figure-3.8 A shows no effect on pRb mRNA in the 
absence of E7. 
Since the metabolic half-life of pRb is inherently controlled by E7 oncoprotein (Boyer et al., 
1996), one might expect that suppression of HPVE7 increases the posttranslational levels of pRb.  
Surprisingly, no pRb increase was observed either in control and in SB treated condition while 
E7 expression was suppressed as shown in Figure-3.8 B (Lane 3 and 7). This could explain that 
residual E7 is sufficient to degrade pRb. Nevertheless the only effect of the E7 siRNA 
transfection on pRb protein, was the presence of the hypophosphorylated pRb (Dyson et al., 
1992; Muenger and Phelps 1993) which was maintained also after treatment with SB, whereas at 
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the control transfected cells both forms (hyper- and hypophosphorylated) of pRb was present 
(Weinberg et al., 1995b; Beijersbergen et al., 1996). Interestingly, the pRb from control 
transfected cells (Figure-3.8 B, Lanes 2 and 4) was still degraded by SB treatment (Lanes 6 and 
8), suggesting the transcription of pRb was not be influenced by siRNA transfection (Figure-3.8 
A). 
Figure-3.8: SB treatment of 
transient transfected HeLa cells 
expressing HPV18-E6/E7 siRNA  
Exponentially growing HeLa cells 
were transfected with 20 µg of the 
respective pSUPER-derived vector 
using calcium phosphate co-
precipitation (Chen and Okayama, 
1987). siRNA-encoding vector 
pSUPER-HPV18-E6/E7 siRNA 
specifically reduces HPV18 E6/E7. 
As mRNA controls mock transfected 
HeLa cells or HeLa cells transfected 
with pSUPER- 
vector expressing siRNA against 
Luciferase or pSUPER empty/vector 
were used. Cells were treated for 24 h 
with Sodium Butyrate, 48 h after 
transfection. (A) RNA analysis: 
siRNA mediated suppression of 
HPV18-E7 transcription was detected 
by Northern blot. After transfer, the 
filter was hybridized with a 
radioactive 32P- labelled probe of 
HPV18. 18S and 28S ribosomal RNA 
are indicated. The transcription level 
of pRb was analyzed by semi-
quantitative RT-PCR. As an internal 
control GAPDH- PCR was 
performed. (B) Western blot 
analysis was performed using anti-
pRb1, anti-HPV18-E7 specific 
antibodies. Equal protein loading was    
confirmed using anti-actin antibody. 
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Although application of E7 specific siRNA did not increase pRb levels per se, but it led to the 
maintenance of the hypophosphorylated pRb upon SB treatment, which consequently could bind 
to its partner E7 to induce the degradation process. 
Since the E7 knock-down experiment failed to abrogate pRb degradation, rhabdomyosarcoma 
cells, harbouring wild type pRb were stably transfected with E7 of HPV16.   
As seen in Figure-3.9 (Lanes 3, 4) HPV16-E7 expression increased after SB supplementation. 
This was paralleled by a down regulation of pRb protein, while in control transfected cells pRb 
expression remained unaffected (Lane 1 and 2). Significantly, both hypo and 
hyperphosphorylated forms of pRb, were decreased in E7 positive TE-671 cells by SB treatment, 
supporting the crucial role of the E7 on enhanced pRb degradation in HDAC inhibition (Lane 4).  
Notably, a concomitant increase of E7 protein is observed with SB (Lane 4), which could induce 
the degradation of pRb per se. However, the disappearance of the hyperphosphorylated form of 
pRb by SB strongly recommends for HDACi mediated effect on pRb degradation that plays the 
major role in this process (Lane 4). 
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Figure-3.9: Ectopic expression of E7 in TE-
671 cells 
Stable transfection of TE-671 cells. Expression 
of HPV16-E7 was analysed by Western blot. 
Cells were incubated for 24 hours with SB. Total 
protein extract 75 µg were separated in (8 %) for 
pRb and in 12% SDS-PAGE for 16E7 analysis. 
After blotting membranes were incubated with 
E7 and pRb antibodies. Control of protein 
loading was done using an anti-actin antibody.   
 
 
 
3.3 pRb degradation induced by HDAC inhibitors is mediated by the 26S proteasome  
 
In order to dissect the role of the individual oncoproteins in HDAC inhibitor induced pRb 
degradation via 26 S proteasome, E6- and E7-immortalised keratinocytes were used.  
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The keratinocytes were treated with SB (6 mM) either in the absence or presence of MG132 (2 
µM), an inhibitor of the proteasome (Rock et al., 1994). Cells were incubated for 8 hours with 
SB and after MG132 addition the incubation proceeded another 16 hours. As shown in Figure-
3.10, HDACi induced pRb degradation in E7-expressing cells was prevented by MG132. 
Interestingly, HDAC inhibitor induces hypophosphorylated form of pRb in E6-immortalised 
keratinocytes, whereas MG132 co-treatment reduced the amount of hypophosphorylated pRb.  
These results confirm that the pRb degradation in the presence of E7 upon HDAC inhibition is 
controlled by the 26S proteasome.   
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Figure-3.10: pRb degradation is proteasome dependent in E7-immortalised keratinocytes. Western blot 
analysis was performed for (A) E7- and (B) E6- immortalised keratinocytes. The cells were treated with SB for 24 
hours for 16 hours MG132 alone or pretreated with SB for 8 hours, than MG132 (2 µM), was added for additional 
16 hours, incubation was continued for 16 hours (lanes 4). Lanes 3 for MG132.  
 
3.4 Inhibitor of serine proteases, TLCK, modifies E7 proteins and inhibits its binding to 
pRb  
 
Taken together, the results from HPV18 positive HeLa cells and HPV16 immortalised 
keratinocytes, show that HDAC inhibitors mediate pRb degradation in an E7-dependent effect. 
To clarify whether the LXCXE binding motif of E7 is directly involved in pRb degradation, cells 
were incubated with tosyl-L-lysine chloromethyl ketone (TLCK), a serine protease inhibitor 
which alkylates the histidine side chain in the active center of trypsin (Schoellmann and Shaw 
1963; Shaw 1970). 
Moreover, Stöppler et al., (1996a) reported that the HPV-E7 Rb-binding core resembles the 
active center of trypsin serine protease, which marks E7 protein as a potential target for TLCK.  
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Structurally the E7 protein consists of two conserved domains (CD-1 and CD-2). The CD1 and 
CD2 domain are important for host-cell transformation. Induction of DNA synthesis is 
contributed to additional elements in CD1 while CD2 contains the direct binding sequences for 
pRb and therefore enables the dissociation of E2F and pRb (Phelps et al., 1992; Brokaw et al., 
1994; Demers et al., 1996). The HPVE7 protein interacts with pRb through a conserved LXCXE 
(aa 22- 26) sequence within the CD-2 domain (Banks et al., 1990; Dyson et al., 1992; Dahiya et 
al., 2000). These residues bind to the pocket region (A/B) of pRb which is placed between aa 
379-772. The scheme in Figure-3.11 shows the interaction domains between pRb (pocket region) 
and HPVE7 (LXCXE motif).  
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Figure-3.11: (Upper part): The structure of the Rb protein. The predicted viral oncoprotein (E7, E1A and SV40 
large T-Antigen) binding site including the A and B pocket regions (379 aa-772 aa), (ID): interdomain (C): C-pocket 
(Lower part): Diagram of the wild type HPV18-E7 protein. The scheme represents the 105 aa at the HPV18-E7 
protein. The position of the Rb-binding core, the casein kinase II phosphorylation sites, and the zinc-binding 
domains are indicated. CDI and CDII is the conserved domain 1 and 2 respectively. 
 
Since TLCK targets E7 by abrogating the binding to pRb, it raised the question whether pRb 
degradation by HDAC inhibitors could be prevented when cells were co-treated with TLCK. 
Consequently, HeLa cells were incubated with TLCK at different concentrations (50, 125, 250 
µM) with or without co-treatment with SB (6 mM) for 16 hours respectively. 
As outlined in Figure-3.12 A, TLCK treatment alone stabilized pRb protein levels in a 
concentration dependent manner (Lanes 3, 4, 5). It has been seen clearly, that pRb proportionally 
increases with TLCK concentrations (50 µM versus 250 µM). Low concentrations of TLCK 
Results  
 
 67
A.
Co
nt
ro
l
SB 50
µM
12
5µ
M
25
0µ
M
50
µM 12
5µ
M
25
0µ
M
reduced SB mediated pRb degradation, whereas higher TLCK concentrations completely 
blocked this process (Lanes 6, 8). In the meantime the expression of the E7 protein was not 
altered by TLCK alone and in combination with SB (Figure-3.12 A).  
To analyse whether TLCK could negatively regulate the transcription of pRb, the level of pRb 
was analysed by RT-PCR. Figure-3.12 B shows that TLCK treatment had no influence on the 
transcription level of pRb, indicating that the reappearance of pRb was on post-transcriptional 
level. Equally, the transcription of HPV18 E7 remains also unaffected even a slight suppression 
was observed in the presence of TLCK (Figure-3.12 C). 
In order to test the functionality of the rescued pRb by co-treatment with TLCK and SB, the 
negatively controlled gene of pRb, cyclin E was analysed. Notably, the expression level of cyclin 
E was down-regulated in response to TLCK co-treatment (Figure-3.12. A), which is correlating 
with the rescued level of the pRb. 
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Figure-3.12: TLCK rescues pRb from SB 
mediated degradation in HeLa cells. 
(A) Western blot analysis of HeLa cells after 
treatment with TLCK (50 µM, 125µM, 250 
µM), SB (6 mM) without or in combination 
with TLCK for 16 h. Total cellular extracts (75 
µg) were separated to analyse the 
posttranslational levels of pRb, HPV18E7, and 
cyclin E by Western blot. Protein loading was 
controlled using anti-actin antibody. (B) RT-
PCR of Rb gene. The respective band for Rb 
(152 bp) is indicated. As an internal control 
GAPDH- PCR was performed. (C) Transcriptional level of HPV18-mRNA was monitored by Northern blot 
analysis, RNA quality is shown in the RNA gel (1%) and equal loading was monitored by actin hybridization. 
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These results emphasize the importance of the direct E7-Rb interaction for the SB mediated 
degradation of pRb. Moreover, it indicates that rescue of pRb from its degradation, down-
regulates the negatively controlled gene cyclin E. 
 
3.4.1 Treatment of HPV16 E7-immortalised keratinocytes with TLCK also rescues pRb 
from its SB mediated degradation  
                                                                                                                                                             
To analyse whether TLCK also prevents pRb degradation in HPV16 E7 positive cells, 
immortalised keratinocytes HPV16 E7- and E6 were included into the subsequent experiments. 
In the presence of E7, TLCK treatment alone reduced pRb protein in a concentration dependent 
manner (Figure-3.13 A, A1 Lanes 3, 4). Nevertheless, higher protein levels of pRb were 
observed after TLCK incubation (Lanes 3, 4), compared to SB treatment alone (Lane 2). Co-
treatment with SB and TLCK blocked pRb degradation (Figure-3.13 A, A1). However, already 
the lower concentration (50 µM) was able to block degradation (comparing Lane 5 with Lane 3), 
while the higher concentration of 100 µM was more effective (comparing Lane 6 with Lane 4).  
In contrast to HeLa cells and E7 keratinocytes, TLCK did not alter the steady state level of pRb 
in E6 keratinocytes. The combination of SB and TLCK diminished the hypophosphorylated pRb 
(Figure-3.13 B, B1). Considering the mRNA levels for pRb, no alteration was observed in both 
E6 and E7 immortalised keratinocytes (Figure-3.13 A2 and B2).  
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Figure-3.13: TLCK rescues pRb from SB mediated degradation in HPV16-E7 immortalised keratinocytes  
Protein extracts were performed from (A.1) E7- and (B.1) E6-immortalised keratinocytes. 75 µg of protein extracts 
were loaded per lane in 8 % (for Rb) or 12 % (for HPV16-E7) SDS-PAGE. Equal loading and transfer was 
monitored by incubation of the membranes with anti-actin antibody. (A.2 and B.2) RT-PCR was prepared for p73. 
GAPDH was used as an internal control and 18S- and 28 S-RNA indicated the quality and equivalent loading on the 
RNA gel. 
 
TLCK treatment of cells induces E7 modifications which in turn prevent E7 binding to pRb. This 
disruption between E7 and pRb binding prevents the pRb degradation upon HDAC inhibitor 
treatment and confirms its direct participation in enhanced degradation of pRb upon HDAC 
inhibition. 
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3.5 HDAC inhibitors SB and TSA upregulate the cyclin dependent kinase inhibitor p21 and 
induces G1 arrest in HeLa cells  
 
The previous results have shown an E7 dependent degradation of pRb in the presence of HDAC 
inhibitors. One main function of pRb is its participation in cell cycle regulation. The pRb 
repression on E2F-mediated transcription is regulated by phosphorylation of pRb by cyclin-
dependent kinases (CDKs) during the cell cycle. This phosphorylation disrupts the association 
between E2Fs and pRb (Buchkovich et al., 1989; Cooper et al., 2001).  
HDAC inhibitor induced cell cycle arrest at the G1/S boundary is associated with induction of 
the CDKN1A (encoding p21WAF1/CIP1), which promotes hypophosphorylation of pRb (Vrana et 
al., 1999; Richon et al., 2000). It has been hypothesized that transcriptional induction of 
p21WAF1/CIP1 is accompanied by an increase in histone acetylation within the p21 promoter 
region, indicating that treatment with HDACi could change expression levels of p21. To verify if 
HDACi treatment influences p21 expression by the promoter, we analysed the expression level 
of p21 in our model systems.  
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Figure-3.14: SB and TSA induce upregulation of p21 in (A) HeLa, (B) E7- and (C) E6- immortalised 
keratinocytes  
Western Blot analysis of cellular extracts obtained from (A) HeLa, (B) E7- and (C), E6-immortalised keratinocytes 
were separated on 12% SDS-PAGE gels. After electrotransfer, the filters were incubated with p21 antibody. Equal 
protein loading was confirmed by incubation of the filters with an anti-actin antibody. Incubation of HeLa cells were 
done for 24 h and for immortalised keratinocytes for 16 h. Control: untreated cells, DMSO: Cells treated with 0.1 % 
DMSO, SB (16 h), and TSA (16 h).  
 
As seen in Figure-3.14, p21 is upregulated upon HDAC inhibition in HeLa as well as in E7- and 
E6- immortalised keratinocytes.  
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3.5.1 Cell cycle analysis after HDAC inhibition 
 
To prove whether the upregulation of p21 upon HDAC inhibition was accompanied by G1 arrest 
(Richon et al., 2000), cell cycle distribution analyses were performed. HeLa cells were treated 
with SB and TSA for 24 and 36 hours, harvested, fixed with 70 % ethanol and analysed by flow 
cytometry. In Figure-3.15 A (24 h) and B (36 h) the proportion of the cells in G1-, S- and G2/M 
phase are presented. A clear G1 arrest was detected with SB. In particular, exposure with SB for 
24 hours increased the percentage of cells accumulating within the G1 fraction from 59,87 % to 
68,03% (A) while extended treatment for 36 hours (B) results in an increase from 33,7 % to 54, 9 
%. After 24 h treatment with TSA there was no significant increase in G1 fraction (A: from 
56,9% to 58,8 %), whereupon an increased accumulation in G1 phase was observed after 36 hour 
incubation (D: 40,53 % to 55,63%). Thus, both HDAC inhibitors induce strong G1 arrest. 
Nevertheless, the most prominent effect was observed with TSA.  
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Figure-3.15: Cell cycle 
distribution after 24 and 36 
hour treatment with SB and 
TSA   
Flow cytometric analyses was 
performed in order to quantify 
the proportion of cells in the 
cell-cycle phases G1, S, G2/M. 
Standard deviations are given 
for three independent 
experiments. The average 
mean of three different 
experiments is given in the 
table below. Treatment of the 
HeLa cells was done with 6 
mM SB or 330 nM TSA for 24 
h (A) and 36 h (B) 
respectively. C33A cells were 
treated for 24 h (C). Control: 
untreated cells; SB: Sodium 
Butyrate (6 mM); DMSO: 
Cells treated with 0.1 % 
DMSO. TSA: Trichostatin A 
(330 nM). 
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Previous results indicate too that SB and TSA are potent inhibitors of cell cycle in HPV18 
positive cervical cancer cells (Finzer et al., 2003). Therefore it was interesting to analyse, 
whether HPV negative cervical cancer cells C33-A were also sensitive to the anti cell-
proliferative effect of HDAC inhibitors SB and TSA. C33-A cells were treated with SB and TSA 
for 24 hours and analysed by flow cytometry. 
Considering the cell cycle analysis (Figure-3.15 C), C33-A cells were also growth arrested, but 
at different stages of the cell cycle. SB treated cells accumulated in the G1 fraction from 46,85 % 
to 63,05 %, whereas TSA treated cells in G2/M fraction (from 13,75 to 54,45%).  
This result demonstrates that SB and TSA induce in HeLa cells G1 arrest while in C33-A cells 
an arrest in G1 as well as in G2/M phase is induced. Furthermore these results indicate that 
HDAC inhibitor mediated cell cycle arrest occur independent of the presence of HPV. 
 
3.5.2 TLCK interferes with sodium butyrate induced G1 arrest  
 
Previous experiments indicate that an SB mediated degradation of pRb necessitates a direct 
interaction between E7 and pRb to enhance the degradation process. Inhibition of the interaction 
with TLCK increases the stability (phosphorylation status) of pRb. Since pRb is one of the major 
regulators of the cell cycle progression, the effects on cell cycle during inhibition of a direct 
interaction between E7 and pRb were analysed. 
As shown in Figure-3.12 A, co-treatment of HeLa cells with TLCK and SB restored pRb which 
reappeared as a hypo- and hyperphosphorylated forms, while the E7 expression was not affected. 
To prove whether restored pRb is able to inhibit the G1 arrest in human HPV positive carcinoma 
cells (Figure-3.15 A and B), expression levels of p21 in HeLa cells were analysed by Western 
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blotting. Cells were co-treated with TLCK (50 µM, 125 µM and 250 µM) and SB (6 mM) for 16 
h.  As seen in Figure-3.16 A, concentration dependent decrease of p21 was observed upon co-
treatment with TLCK and SB (Lanes 6, 7, 8).  
This might lead to reduced G1-arrest induced by HDAC inhibitor. In order to prove this effect in 
specific cell cycle phases, cell cycle analyses were performed (Figure-3.16 B). 
As already shown, SB leads to accumulation of cells in G1 phase (from 47,5 % to 72,2 %) of the 
cell-cycle. TLCK alone has no prominent effect on the distribution of cells in the different 
phases of the cell cycle compared to control conditions (from 47,5% to 56,65%). Whereas TLCK 
and SB co-treatment led to a significant reduction of the percentage of cells in G1 (from 72,20 % 
to 31,40%), a dramatic increase of cells in S phase (from 8,60% to 47%) compared to SB 
treatment alone. 
 
Figure-3.16: TLCK reduces 
the SB mediated G1 arrest in 
HeLa cells.  
(A) Western blot analysis of 
HeLa cells after treatment with 
TLCK (50 µM, 125 µM, 250 
µM), SB (6mM) without or in 
combination with TLCK for (16 
h). Total cellular extracts (75 
µg) were separated to analyse 
the posttranslational levels of 
p21 by Western blot. Protein 
loading was controlled using 
anti-actin antibody. (B) Cell 
cycle distribution in HeLa cells. 
Flow-cytometric analysis: The 
bars indicate the percentage of 
cells within different cell cycle 
phases (G1, S, G2/M). Standard 
deviations are given for three 
different experiments. The 
indicated cells were incubated 
with SB (6 mM), TLCK (125 
µM for) alone and co-incubated 
with SB and TLCK 
(corresponding concentration) for 24 hours. As control, cells with medium-change (DMEM) were used.  
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This result suggests that TLCK also affects the activity of HDAC inhibitors independently of E7 
oncoprotein. Hence, the inhibitory effect of TLCK on HDAC inhibitor induced pRb degradation 
is apparently not only due to E7 modification but also due to reduced HDACi activity which 
occurs only at higher TLCK concentrations. 
 
3.6 HDAC inhibitors SB and TSA induce apoptosis only in the presence of HPV   
 
Beside the cell cycle regulatory function, HDAC inhibitors are also able to induce apoptosis in  
tumor cells (Bolden et al., 2006).  
Inactivation of pRb can stimulate proliferation and apoptosis. The “promoter-specific” regulation 
of pRb/E2F transcription complex involves the expression of S phase genes through 
phosphorylation of pRb and the expression of the apoptotic genes through the pRb degradation 
(Chau et al., 2002; Chau and Wang 2003). 
Inductions of the genes which are essential for the G1 to S phase transition are dependent on the 
transcription factor E2F-1. In addition to the proliferative effects, E2F-1 is also involved in 
apoptosis (Nevins, 1998). E2F can function as a proapoptotic transcription factor if it is freely 
available in the cell. It induces apoptosis by targeting genes such as the p53 homologue p73 
(Phillips and Vousden, 2001). 
A pronounced degradation of the anti-apoptotic protein pRb (Haas-Kogan et al., 1995 and 
Figure-3.1) without any decrease in the transcription factor E2F-1 (see also Figure-3.5) 
presumably accounts for the final appearance of the distinct apoptotic features.  
Therefore the fate of the HeLa cells was analysed by flow cytometry after prolonged HDAC 
inhibitor treatment. HeLa cells were treated as mentioned in Figure-3.15.   
Extending SB incubation time increased the amount of the apoptotic cells. The observed effects 
were more pronounced in the presence of TSA. As seen in Figure-3.17 A, about 3% of the cell 
population were accumulated after 24 h with SB in the sub-G1 fraction. This portion of the cell 
population represents apoptotic cells. This value rose to 9% when the cells were incubated for 36 
h (Figure-3.17 B). In the case of the TSA, nearly 11% of the cells accumulate in the sub-G1 
fraction after 24 h. This value rose to 13% after 36 hours.   
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Figure-3.17 A and B: 
Induction of apoptosis in 
HeLa cells after 24 and 36 
hour treatment with SB and 
TSA.  
HeLa cells were treated with 6 
mM SB or 330 nM TSA for 24 
h (A) and 36 h (B) 
respectively. The bars indicate 
the percentage of cells in sub-
G1 (= apoptotic cells). 
Standard deviations are given 
for three independent 
experiments. The average 
mean of three different 
experiments is given in the 
table below. Control: untreated 
cells; SB: Sodium Butyrate (6 
mM); DMSO: Cells treated 
with 0.1 % DMSO. TSA: 
Trichostatin A (330 nM).  
 
 
 
This result demonstrates that treatment of Hela cells with both HDAC inhibitors induces 
apoptosis which is increased when cells are incubated for longer than 24 hours.  
Since it was observed that interaction between E7 and pRb was essential for the HDAC inhibitor 
mediated degradation of pRb and also an unaltered level of pRb in HPV negative cervical 
carcinoma cells by HDAC inhibitor treatment (Figure-3.2), it was mandatory to analyse whether 
HDAC inhibitors also show apoptotic features in the absence of E7. To study this in greater 
detail the cervical carcinoma cell line C33-A was used, which is free of HPV infection (Heilman 
et al., 1980). Flow cytometric analysis revealed that these cells did not accumulate at the sub-G1 
fraction with SB, while TSA induced apoptosis to a certain extent (cells in sub-G1= 3%) as seen 
in Figure-3.17 C. 
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C.
 
Figure-3.17 C: HDAC 
inhibitors SB and TSA 
don’t induce apoptosis in 
C33-A cells  
C33a cells were treated with 6 
mM SB or with 330 nM TSA 
for 24 h. (A) The bars 
indicate the percentage of 
cells in sub-G1 (= apoptotic 
cells). Standard deviations are 
given for three independent 
experiments. The average 
mean of three different experiments is given in the table below. Control: untreated; SB: Sodium Butyrate; TSA: 
Trichostatin  
 
In order to confirm apoptosis induced by SB and TSA treatment in HPV positive cells, PARP 
cleavage was used as an internal marker (Finzer et al., 2004). This process can be monitored by 
caspase-3 activation. Proteolytic cleavage of poly ADP-dependent-ribose polymerase (PARP), a 
natural substrate for caspase-3, produces two fragments of 116 kDa and 85 kDa (Lazebnik et al., 
1994). Western blot analysis demonstrate that the expected fragment of 85 kDa fragment 
appeared only in HPV positive cells HeLa and SW756, while it is absent in HPV negative 
cervical cancer cells C33-A (Figure-3.17 D). 
 
Figure-3.17 D: Cleavage of PARP in HPV 18 
positive and HPV negative cells.  
HeLa, SW756 and C33A cells were treated with SB 
(6 mM) and TSA (330 n) Western blot analysis: 75µg 
of cellular extracts were separated in 8% SDS-PAGE 
gels. After incubation with a monoclonal antibody 
against PARP, equal protein loading was confirmed 
by incubating the filters with an anti-actin antibody 
for individual cell lines. Control: untreated cells, 
DMSO: Cells treated with 0.1 % DMSO. Treatments 
for SB and TSA were done for 24 h. The 
characteristic cleavage product (85 kDa fragment) of 
PARP is marked by asterisks. 
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3.6.1 SB and TSA induce apoptosis in HPV positive cells via the proapoptotic gene p73 
 
As a chemotherapeutic drug HDACi can induce cell death by activating either an intrinsic or 
extrinsic apoptotic pathway (Johnstone et al., 2002; Minucci et al., 2006).   
Notably it has been described that p73 is one of the E2F-1 responsive genes which exhibits pro-
apoptotic properties and is up regulated at the transcriptional level after SB treatment (Finzer et 
al., 2004)  
The p73 belongs to the p53 family that transactivates several genes such as, p21, p53R2, PUMA, 
BAX involved in cell cycle control and apoptosis (Melino et al., 2002). The tumor suppressor 
gene TP73 encodes two different proteins which exhibit opposite effects: The p73 isoform 
TAp73 contains a transactivation (TA) domain which functions as a pro-apoptotic protein, while 
the ΔNp73 has a shorter amino terminus, without the TA domain, functioning as anti-apoptotic 
protein. The apoptosis induced by TAp73 involves the mitochondrial pathway (Ramadan et al., 
2005).  
In order to verify whether SB induced apoptosis involves the induction of the p73 upregulation 
in HeLa cells RT-PCR upon SB treatment for 24 h was carry out. As depicted in Figure-3.18 A, 
p73 is upregulated at the transcriptional level upon SB treatment. Moreover this transcriptional 
effect is also monitored by Western blotting for SB and TSA (Figure-3.18 B). 
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Figure-3.18 A: HeLa cells were treated with SB (6 mM) for 16 h. (A) RT-PCR of p73 gene. The respective band for 
p73 (1636 bp) is indicated. As an internal control, GAPDH- PCR was performed. (B) Western blot analysis of p73 
after treatment with SB (6 mM) and TSA (330 nM)  for 24 h. Total cellular extracts (75 µg) were separated in a 10 
% SDS-PAGE. The membrane was incubated with a rabbit polyclonal antibody specific for p73. Protein loading 
was controlled using anti-actin antibody.  
 
This result indicates that SB strongly induced the transcription of the p73 in HeLa cells which is 
involved in the intrinsic pathway of apoptosis. 
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3.6.2 TLCK treatment leads to a suppression of the HDAC inhibitor induced proapoptotic 
p73 transcription 
 
The previous results showed that the interaction between E7 and pRb is essential for the HDAC 
inhibitor induced apoptosis in cervical cancer cells (Figure-3.12; 3.13 A and 3.15).  
TLCK can disrupt the interaction between pRb and E7 and restores pRb (Figure-3.12; 3.13 A). It 
was therefore expected that this should also lead to a suppression of E2F-1 induced p73 
transcription. Moreover E6 keratinocytes were analysed as a negative control since pRb is not a 
direct interaction partner of E6.  
Therefore the transcriptional level of p73 was investigated by RT-PCR upon co-treatment with 
TLCK. As shown for HeLa cells (Figure-3.19 A) as well as for E7 immortalised keratinocytes 
(Figure-3.19 B), TLCK inhibits SB induced p73 mRNA (TAp73) in a strictly concentration 
dependent manner. In the case of E7 immortalised keratinocytes a higher concentration of 100 
µM TLCK is needed to completely block p73 induction. This reduction of p73 was also observed 
at the protein level (Figure-3.19 C). Surprisingly, E6 immortalised keratinocytes also present a 
moderate up regulation of p73 transcription by HDAC inhibition (Figure-3.19 D) which is 
accompanied with a slight up regulation on the protein level (Figure-3.19 E).  
 
These results indicate that TLCK mediated E7 modification is also able to impair the induction 
of p73 which is strongly induced by SB. Consequently, E2F is not able to activate the 
proapoptotic genes p73. Moreover this result also highlights the role of the presence of E7 for the 
sensitization of HDAC inhibitor induced apoptosis. 
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Figure-3.19: TLCK can inhibit the SB mediated p73 transcription 
HeLa cells were treated with TLCK (50 µM, 125 µM, 250 µM), SB (6 mM) without or in combination with TLCK 
for 16 h. (A) RT-PCR of p73 genes. The respective band for p73 (1636 bp) is indicated. E7- and E6- immortalised 
keratinocytes were treated with TLCK (50 µM and 100 µM), SB (6 mM) without or in combination with TLCK.  
RT-PCR was performed for p73 mRNA expression for E7 and E6 keratinocytes respectively (B and D). The 
respective band for p73 (263 bp) is indicated. As an internal control GAPDH-PCR was performed. Total cellular 
extracts (75 µg) of E7 and E6 keratinocytes were separated in a 10 % SDS-PAGE. The membrane was incubated 
with a rabbit polyclonal antibody specific for p73. Protein loading was controlled using anti-actin antibody (C and 
E).
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IV. DISCUSSION 
 
4.1 HDACi mediated pRb degradation requires the presence of the HPVE7  
The presented work was specifically focused on the role of E7 in tumor suppressor protein pRb 
degradation following HDAC inhibition. 
Initial observations in the HPV 18 positive cervical carcinoma cells HeLa demonstrated that the 
degradation of pRb upon SB, occurs only in the presence of E7 oncoprotein. pRb degradation  
following HDACi administration has previously been reported by Finzer et al., (2001). Analysis 
of SW756 cells demonstrated that this effect is common to other HPV18 positive cervical cancer 
cell lines and that it is independent of the viral integration sites, since Hela cells are known to be 
positive for multiple truncated copies of HPV18 integrated at four distinct chromosomal loci 
(Schwarz et al., 1985; Popescu et al., 1987a), while SW756 cells harbour multiple truncated 
copies of HPV18 located at a single integration site (Popescu et al., 1987b). In addition, the 
origin of the cancer cells appears to have no effect as HeLa derived from adenocarcinoma 
(Boshart et al., 1984; Schwarz et al., 1985) and SW756 from squamous cell carcinoma 
(Freedman et al., 1982). To rule out the possibility that the tumorigenic potential phenotype of 
the cell rather than the presence of HPV was the cause of this observed phenotype, the 
Stanbridge cell system and HPV negative cervical cancer cell were used. The presented results 
showed a HPV dependency, while the tumorigenic phenotype was not influenced by HDACi 
treatment (Figure-3.2 and 3.3). 
Interestingly, in HPV negative cell lines (C33-A and HT-3 cells), no pRb degradation was 
observed after treatment with HDACi, rather they had different pRb phosphorylation states. 
Furthermore, these cell lines harbour mutations in the RB gene. These mutations (exons 20 in 
C33-A and exon 13 in HT-3) are located in the pRb growth inhibitory domain, the so called 
“pocket domain” which is necessary for its binding to viral and many cellular proteins. This 
domain can be differently hyperphosphorylated (Scheffner et al., 1991). Therefore it is likely that 
the phosphorylation state of pRb upon HDACi application could be a confounding factor. 
In HT-3 cells additional hyperphosphorylated bands were observed (Figure-3.2). This different 
phosphorylation status of pRb in C33A and HT-3 cells could also be caused by the different 
mutations. Since differences between the phosphorylation states of both C33-A and HT-3 cells 
were observed, it is possible that this is also due to the presence of different mutation. Moreover 
Rb degradation in the presence of E7 in individually E7-immortalised keratinocytes confirms 
this crucial functional link (Figure-3.4 A), which is also shown by Finzer et al., (2001). Given 
that the presence of E7 is a prerequisite for HDAC inhibitor induced enhanced degradation of 
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pRb, it would be interesting to prove whether introduction of HPV E7 in C33-A and HT-3 cells 
would sensitize the cells for HDACi mediated pRb degradation. 
The observed pRb degradation in these cells could be explained by the presence of HPV E7 
oncoprotein. E7 preferentially bind to hypophosphorylated form of pRb (Munger et al., 1992; 
Imai et al., 1991) and can at least abrogate the binding of pRb to E2F. Subsequently, degradation 
of pRb by E7 promotes entry to S phase (Boyer et al., 1996; Jones et al., 1997a). Though, both 
mechanisms are dependent on stochiometry between pRb and E7 and the presence of 
hypophosphorylated pRb in cervical cancer cells. Here a synergistic effect of HDAC inhibitors 
and E7 on the destabilisation of pRb was observed.  
In contrast to E7 immortalised keratinocytes, hypophosphorylated pRb in E6 keratinocytes 
following HDAC inhibition was observed. pRb hypophosphorylation following HDACi 
application has also  been described in other cell systems (Wang et al., 2000; Wharton et al., 
2000; Emanuele et al., 2004; Sambucetti et al., 1999).  
pRb protein inactivation by HPV E6 can be due to hyperphosphorylation and involves increased 
activity of cyclin A/CDK2. Hyperphosphorylation of pRb allows the transcription of cyclin E 
and cyclin A which are important for the maintenance of cell cycle progression. Furthermore, 
strong down-regulation of p21, which inhibits the cyclin A/CDK2 activity, could also contribute 
to the E6 mediated deregulation of the G1/S transition (Malanchi et al., 2002; Malanchi et al., 
2004). E6 is not able to bind and degrade pRb like E7, therefore the presence of 
hypophosphorylated pRb was due to the upregulation of cyclin-dependent kinase inhibitors such 
as p21 and p27 after HDACi (for p21 see Fig.-3.14).  In turn, this suppresses activation of the 
cyclin-dependent kinase complexes (Richon et al., 2000; Finzer et al., 2001). 
The presence of E7 upon HDACi treatment is likely due to the increased stability of E7, 
mediated by posttranslational modification such as acetylation (Caron et al., 2005). Studies have 
shown that E7 can independently interact with pCAF acetyltransferases, (Huang and McCane, 
2002; Avvakumov et al., 2003) in vitro and in vivo which results in disruption or direct targeting 
of the pCAF complex to new substrates, including other E7-binding proteins (Bernat et al., 
2003). The acetyltransferase pCAF, has been reported to function as a coactivator for variety of 
transcription factors such as p53 (Sakaguchi et al., 1998; Liu et al., 1999). 
HDACi do not exert their pleiotropic effect solely by direct regulation promoter activity by 
histone hyperacetylation (Bolden et al., 2006). It is also known that HDAC molecules can bind, 
deacetylate and regulate the activity of a number of other proteins, including transcription 
factors. For example, the gene regulatory activity of transcription factors E2F1, p53, STAT1, 
STAT3 and NF-κB can be modulated through direct acetylation and deacetylation of the factors 
themselves (Gu et al., 1997; Martinez-Balbas et al., 2000; Chen et al., 2001; Yuan et al., 2005). 
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Similarly acetylation by HDACi may contribute to an extended half-life of E7 and increased 
activity. 
However, considering the experiments in which the cell lines HeLa, 444 and CGL-3 were used, a 
reduction of E7 protein upon treatment with TSA (Figure-3.3) was observed. As previously 
reported, HPV transcription can be transiently suppressed by HDAC inhibition, but it returns to 
basal expression levels after 12 to 16 hours treatment (Finzer et al., 2003). Therefore the 
observed reduction of E7 protein by TSA is a posttranslational effect. TSA has been shown to be 
a more potent inhibitor of HDAC molecules than SB (Finnin et al., 1999; Matsuyama et al., 
2002) which is even active in nanomolar concentrations. For this reason different results could 
be observed after the same incubation time. Indeed pRb degradation was observed in E7 
immortalised keratinocytes upon TSA treatment for 16 hours while E7 viral protein was not 
degraded (Figure-3.4 A).   
Furthermore it has been shown that TSA treatment down-regulates cellular proteins via 
ubiquitin-dependent proteasomal degradation. For example, Alao et al., (2004) reported about a 
proteasomal degradation of cyclin D1 after TSA treatment, where the regulatory component of 
SCF complex (Jackson and Eldridge, 2002), SKP2/p45 is upregulated. From the literature it is 
known, that SKP2/p45 is also involved in the ubiquitin–dependent proteasomal degradation of 
E7 (Wang et al., 2001; Oh et al., 2004). It is possible that longer treatment with TSA can also 
induce a proteasomal degradation of E7 in a SKP2/p45 dependent manner. Nevertheless, the 
upregulation of the SKP2/p45 was not observed upon treatment with SB, since previous data by 
our group demonstrate its suppression which in turn upregulates the cyclin-dependent kinase 
inhibitor p27 (Finzer et al., 2001). Therefore the role of the SKP2/p45 in down-regulation of the 
E7 protein needs to be further clarified considering the appropriate incubation times.  
Interestingly, a reduced E7 protein level was observed in SW756 cells. Compared to the other 
HPV18 positive cells, this reduction was correlating with a reduced effect on pRb degradation 
after SB treatment. However, the mechanism behind the slight reduction of E7 (whether it be a 
posttranslational or transcriptional event), needs to be clarified.  
To clarify the functional link between E7 and pRb degradation upon HDACi treatment two 
different experimental approaches were used: 
At first, the transcription of the HPV E7 was knocked down by E7 siRNA in HeLa cells. Since 
the postranslational level of pRb is inherently controlled in HPVE7 expressing cells (Boyer et 
al., 1996), one would expect an upregulation of the pRb protein in response to HPV mRNA 
suppression. However, only the hypophosphorylated pRb was produced which appears to be 
completely maintained upon SB treatment (Figure-3.8 A and B). The hypophosphorylation of 
pRb after transcriptional suppression of HPV18 was also reported by the group of Goodwin 
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(2000). In contrast, they reported a dramatic up-regulation of the hypophosphorylated pRb and 
repression of the pRb/E2F regulated genes (Goodwin et al., 2000) upon suppression of the HPV 
transcription.  
However, the presence of hyposphosphorylated pRb could also be explained by abolishment of 
other E7 mediated cellular activities. For example, disruption of the interaction between cyclin A 
and cyclin E could inhibit the activation of the cyclin/CDK complexes (Zerfass et al., 1995). 
Additionally it is possible that suppression of HPV E7 leads to the disruption of the activity of 
the CDK inhibitors p21WAF/CIP1 and p27KIP1 which in turn inhibits the activity of cyclin/CDK 
complexes (Jones et al., 1997). Therefore, to assess the role of the cyclins (A, E, and D) in 
addition to the role of the CDKi (p21 and p27) under these circumstances needs to be clarified.  
As the E6 and E7 proteins of HPV18 are both translated from common polycistronic transcripts 
(Schneider-Gaedicke et al., 1986), it is technically feasible to concomitantly block the expression 
of both genes by one single siRNA species (Hall et al., 2003). Indeed recent report from the 
group of Kuner et al., 2007, showed a silencing of HPV18 E6/E7 by using pSUPER-siRNA 
directed against sequence motives common to all HPV18 E6/E7-encoding mRNAs. In agreement 
with the presented result in Figure-3.8 A they were also able to demonstrate the silenced E7 
transcription. As there are currently no antibodies available to reliably detect the presumably 
very low endogenous E6 protein levels in HeLa cells, inhibition of E6 following siRNA 
expression was assessed functionally. They observed increased p53 levels, which is 
proteolytically degraded by E6 (Scheffner et al., 1990) and an accompanied increase of p21, 
which is a transcriptional target for p53 (El-Deiry et al., 1993; Kuner et al., 2007). Interestingly, 
hyperphosphorylated pRb was observed in response to the siRNA transfection in our results 
(Figure-3.8). It is conceivable that upregulation of p21 in response to E6 silencing can inhibit the 
cyclin-CDK complexes which are responsible for the phosphorylation of the pRb (Weinberg, 
1995a; Sherr and Roberts 1999). Nevertheless experiments need to determine the relationships 
between downregulation of the pRb hyperhosphorylation and E6 silencing.  
Additionally, to support the hypothesis, the E7 gene was introduced into the HPV negative cell 
line TE-671, which possesses a full functional pRb. Obviously enhanced degradation of pRb in 
the presence of HDACi confirms the particular importance for HPV16-E7 in those cells (Figure-
3.9). Down-regulation of the hypophosphorylated pRb upon SB treatment indicated the 
stabilisation of the E7 protein. However, further experiments should be conducted in order to 
clarify the stabilisation of E7 upon HDAC inhibition. Accordingly, it was confirmed that the 
delivery of E7 induces an enhanced SB mediated degradation of pRb.  
The observed overexpression of the E7 protein by SB per se might be explained by the non-
specific promoter (in our case CMV- promoter) induction by SB which is reported by Nan et al., 
 
Discussion 84 
(2004). Since we observed a concomitant increase of E7 upon HDAC inhibition in E7 positive 
TE-671 cells, the pRb degradation cannot be attributed to only a SB-mediated effect. 
Nevertheless, comparison of the TE-671 cells (Iolascon et al., 1996; Xia et al., 2002) with the 
HPV negative cervical cancer cells C33-A and HT-3 cells, which are harbouring mutations in 
RB1 gene, one can predict that SB mediated enhanced degradation of pRb is strongly dependent 
on the presence of E7 protein (Figure-3.2 and 3.9). It would be interesting to monitor whether 
these cells could be sensitized to HDACi mediated degradation of pRb after introduction of a 
truncated E7-form which is unable to bind pRb. 
In a further approach, both recombinant pRb and E7 plasmid were transfected in a HPV and pRb 
negative cell line Saos-2 (Osteosarcoma cell line). Nevertheless, the initial attempts remained 
without success, due to the unspecific induction of plasmid promoters by HDACi. 
 
4.2 HDACi mediated pRb degradation increases the expression of the negatively regulated 
cyclin E  
pRb is sequentially phosphorylated during entry into S phase by Cyclin D/CDK4/6 complexes 
and Cyclin E/CDK2 complexes. As a consequence, E2F can transactivate its responsive genes 
and finally permits cells to enter into S phase. Under normal conditions, hypophosphorylated 
pRb binds to E2F and inhibits the transcription of negatively regulated genes (Weinberg et al., 
1996). This partially occurs due to the recruitment of the HDAC1 on E2F responsive promoters 
(Brehm et al., 1998; Magnaghi-Jaulin et al., 1998; Brehm and Kouzarides et al., 1999a and 
1999b).  
As expected, cyclin E gene, which is negatively regulated pRb was upregulated in HeLa, 
SW756, 444, CGL-3 and in E7 and E6-immortalised keratinocytes upon SB and TSA treatment 
(Figure-3.4 A). The induction of cyclin E is primarily explained by derepression of the E2F 
binding sites on the cyclin E promoter (Geng et al., 1996). Therefore the degradation of pRb in 
HPV18 positive and in E7 immortalised cells upon HDAC inhibition is a prerequisite for 
induction of cyclin E.  
Also an induction of cyclin E expression in control conditions was observed. This is explained 
mainly due to the presence of E7 which can induce the expression of the cyclin E (Zerfass et al., 
1995) as E2F mediated repression is lost.  
Since HDAC inhibition was shown to downregulate cyclins D and A, and to suppress CDK2 
activity (Finzer et al., 2001), one would expects that this finally leads to hypophosphorylated 
pRb and turns off the E2F-responsive genes. Thus, the increase of cyclin E expression upon 
HDAC inhibition is contradictory to its effect on cell cycle control, where it promoted 
accelerated entry from G1 to S phase (Resnitzky et al., 1994; Ohtsubo et al., 1995). Nevertheless 
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this shows that HDACi potentiate the effect of E7 on the cyclin E expression, whereas 
antagonizing the effect of E7 on other cyclins by inducing their degradation (Finzer et al., 2001), 
such as cyclin D (Alao et al., 2004) and cylin A (Schulze et al., 1995).  
The presence of hypophosphorylated pRb (which was still able to repress the transactivation of 
E2F), was also associated with upregulation of cyclin E in E6-immortalised keratinocytes. This 
suggests that another transcriptional control mechanism was involved. Furthermore, this is 
supported by the fact that E2F was also decreased, which suggests the two mechanisms are not 
directly linked (Figure-3.5 B). The transcription of cyclin E has been shown to be E2F-
dependent, but recently, several investigators have demonstrated that Sp1 transcription factor has 
a synergistic effect with E2F on the transcription of cyclin E and other E2F responsive genes 
such as DHFR (Karlseder et al., 1996; Lin et al., 1996; Vogt et al., 1999). Among these studies 
Kim et al., (2006) provide evidence that  HDAC inhibitor apicidin increases hyperacetylation of 
histones at cyclin E promoter region containing specific Sp1 sites, resulting in an induction of 
cyclin E expression through Sp-1 dependent and E2F-independent mechanisms. Furthermore, 
another transcription factor Myc was shown to be involved in upstream regulation of the cyclin E 
and plays a critical role in sustaining an E2F-independent, G1/S–promoting mechanism by 
regulating the cyclinE/CDK2 activity (Santoni-Rugiu et al., 2000). According to this, Santoni-
Rugiu et al., were able to demonstrate that Myc activates cyclin E transcriptionally and is 
capable of promoting G1/S transition in parallel to Rb/E2F pathway (2000).  
Taking these studies into consideration it is conceivable that transcriptional regulation of cyclin 
E upon HDAC inhibition in E6 keratinocytes involves additionally other transcription factors.  
As shown by Figure-3.5 B, E2F levels remain unchanged in HPV18 positive cells HeLa, 444, 
CGL-3 and in E7-immortalised keratinocytes. The presence of the E2F upon HDAC inhibition 
can be explained by the increased protein stability due to the acetylation as it is previously 
reported by several studies (Bhalla, 2005; Caron et al., 2005; Minucci et al., 2006). Thus, the 
HDACi mediated increase of E2F stability is due to activated pCAF which has an HAT activity. 
Consequently, E2F acquires increased DNA binding affinity, enhanced transactivation capacity 
and prolonged half-life (Martinez-Balabas et al., 2000; Ianari et al., 2004). 
The abundance of E2F can be regulated at the level of transcription (Johnson et al., 1994) and on 
its DNA binding (Dynlacht et al., 1994) capability. Moreover the hypophosphorylated pRb 
appears to be in fact a specific protector of E2F from proteasomal degradation (Hateboer et al., 
1996; Hofmann et al., 1996). Therefore the half-life regulation of E2F is not a monocausal event. 
The activity of pRb can be increased also by HDACi (Lindemann et al., 2004) via acetylation as 
a non-histone target. Interestingly, Chan et al., (2001) demonstrated that acetylation of pRb can 
inhibit its phosphorylation by cyclin E/CDK2.  Moreover, studies of the group of Brown (2002) 
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reported that the role of the six-lysine basic patch of pRb on the rim of the LXCXE binding site 
is essential to relieve from E2F. Amongst others, the effect on E2F transactivation, the 
mechanism and biological relevance of pRb acetylation remain unclear. 
Previous work reported that the ubiquitin ligase p45 (SKP2) was reduced upon SB treatment 
(Finzer et al., 2001) which plays a role in ubiquitin-mediated proteasomal degradation of E2F 
(Marti et al., 1999). It is still questionable why under these condition E2F level is not 
upregulated, since it was shown that ectopic p45SKP2 expression can induce premature 
degradation of E2F (Marti et al., 1999). Whether this discrepancy reflects an equilibrium 
between the accumulation of E2F and its preferential degradation when pRb is absent remains to 
be answered. Furthermore, the observed unchanged level of E2F in E7 immortalised 
keratinocytes needs to be clarified prior to and after delivery of E7-expression vectors. 
Interestingly E2F is down-regulated in the presence of the hypophosphorylated pRb in E6 
keratinocytes. This seems to be contradicting (Figure-3.5 B) because of the upregulation of the 
cyclin E in these cells (see above).  
One explanation for that could be an autoregulatory loop by which E2F regulates its own 
expression. It is known that the transcription of the SKP2/p45 is directly regulated by E2F itself. 
The increased expression would then efficiently induce the degradation of E2F.  
Nevertheless the expression levels of E3 ligase p45SKP2 in E6 and E7 immortalised keratinocytes 
needs to be investigated to explain the down regulation of E2F upon SB. 
Further assumption of an inefficient binding of hypophosphorylated pRb with E2F needs to be 
confirmed by co-immunprecipitation analyses. So far evidence still failed to clarify the role of 
both acetylated pRb and E2F and their interaction between the pRb-pocket C (Whitaker et al., 
1998) and E2F transactivation domain upon SB will be the objective for further studies. 
 
4.3 Physical association of pRb and E7 is important for the HDACi mediated degradation    
of pRb 
To further investigate the crucial role of the direct interaction between E7 and pRb upon HDACi 
treatment, a strategy employing the postranslational modification of E7 by the serine protease 
inhibitor TLCK was used. Consequently, co-treatment with TLCK stabilised the 
hypophosphorylated and hyperphosphorylated pRb (Figure-3.12 A; 3.13 A1). The recovery of 
the hypophophorylated pRb was mostly due to the modified E7 which was unable to directly 
interact. Under normal conditions, the E7 binds pRb via its LXCXE motif (Watanabe et al., 
1990; Stirdivant et al., 1992) and is responsible for pRb degradation by proteasome mediated 
pathway (Wang et al., 2001). Modification of E7 by TLCK is caused by alkylation of the 
cysteine residue at the LXCXE binding motif (Stöppler et al., 1996) which is directly involved in 
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the association with Rb pocket domain (Lee et al., 1998). Studies in immortalised E7 
keratinocytes clearly demonstrate the individual role of the E7 in this context. Nevertheless the 
levels of the accumulated pRb are higher in HeLa than in E7-Keratinocytes. Remarkably, the 
repression activity of the recovered hypophosphorylated pRb correlates with the decreased level 
of cyclin E expression (Figure-3.12 A).   
In addition, the appearance of the hyperphosphorylated pRb in HeLa, E7 and E6 immortalised 
keratinocytes can be explained by the decreased levels of p21, which was shown to be 
downregulated in a dose dependent manner with TLCK (Figure-3.16 A). Therefore the activity 
of Cyclin/CDK2, 4 and 6, which are responsible for the cell cycle dependent phosphorylation of 
pRb (Weinberg et al., 1995a; Sherr et al., 1995a) needs to be further investigated.  
Furthermore, it is conceivable that E7 modification could prevent  E7 to perform other cellular 
activities which are important for the cell cycle progression, such as direct activation of cyclin A, 
D and inhibition of the CDK inhibitor p21 (Zerfass et al., 1995; Zwerschke et al., 2000; zur 
Hausen 2002). Moreover previous results by our group demonstrated that HDACi treatment 
downregulates the expression of cyclins such as D and A (Finzer et al., 2001). Therefore the 
involvement of the cyclin D and A in the hyperphosphorylation of pRb upon TLCK and SB co-
treatment needs to be clarified. Interestingly, p21 is downregulated even in the presence of the 
modified E7. Thus, that might occur in an E7 independent manner. However, whether this 
downregulation occurs at transcriptional level or not needs to be demonstrated. 
It is obvious that TLCK synergize the activity of E7 in the HPV transformed cells by 
counteracting the pleiotropic effects of HDAC inhibitors in order to support the cell progression. 
Nevertheless, a clear demonstration of the reduced association between E7 and pRb upon TLCK 
co-treatment with HDACi is the objective of further co-immunoprecipitation experiments. 
Previous studies have shown that E7 is phosphorylated by casein kinase II (CKII) and, suggest 
that phosphorylation by CKII is a significant factor in regulating the function of E7 (Barbosa et 
al., 1990; Storey et al., 1990; Firzlaff et al., 1991).  Inhibitors of the CKII class such as TBB (4, 
5, 6, 7-tetrabromobenzotriazole) (Sarno et al., 2001), were used to inhibit the E7 function on 
HDACi mediated pRb degradation. The experiments showed that TBB was not able to 
counteract the effect of HDACi on pRb degradation. This suggests that phosphorylation of E7 
does not contribute to HDACi induced pRb degradation (data not shown). 
Other possible strategies can help to understand and confirm the direct involvement of E7 in pRb 
degradation such as disrupting the interaction between E7 and pRb by using the peptide aptamer 
technique. Thus, Nauenburg et al., (2001) demonstrated that a specific artificial peptide which 
can bind with a high affinity to E7 can knock out the function of E7 such as reducing the 
proliferation of NIH3T3 (Mouse embryonic fibroblast cells) cells expressing E7 protein. 
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Conversely, posttranslational modification of pRb can also be considered as a strategy in order 
study the interaction between this both proteins. For example SUMOylation of pRb disrupts the 
interaction with E7 (Ledl et al., 2005) and therefore can be serve for our purpose. 
 
4.4 Proteosomal degradation of pRb in HPV positive cells 
The degradation of the tumor suppressor protein pRb as a short lived protein (Wang et al., 1994; 
Knudson and Wang, 1997) is controlled by proteasome pathway. In normal as well as in HPV 
transformed cells, pRb degradation requires the presence of the 26S proteasome (Boyer et al., 
1996). Thus, treatment of E7 keratinocytes with the proteasome inhibitor MG132 revealed and 
confirmed the role of proteasome in HDACi mediated pRb degradation (Figure-3.10) Moreover, 
the recovered hypophosphorylated pRb further support the crucial role of E7 protein in this 
specific enhanced degradation process of pRb. This result is in agreement with the initial 
observation in HeLa cells which were shown by Finzer et al. 2004. Notably, blocking the 
proteasome should lead to an increase of hypophosphorylated pRb, also demonstrating the 
requirement of the proteasome for HDACi mediated degradation of pRb. Since pRb can be 
posttranslationally acetylated by binding to p300/CBP, which is a transcription factor with 
intrinsic histone acetyltransferase (HAT) activity, the stability is increased by treatment with 
HDACi. According to this, SB treatment switches the HAT/HDAC equilibrium within the Rb 
complex in favour of HAT. Thus Chan et al., (2001) reported that certain lysine amino acids at 
positions 830 and 884 are enhanced acetylated, which in turn increase the level of 
hypophosphorylated pRb after MG132 incubation. 
However, experiments need to be performed in order to clarify the functionality of the recovered 
pRb such as binding to E2F and the re-establishment of the inhibitory effects on cyclin E 
expression. Conversely, the observed decrease of hypophosphorylated pRb in E6 keratinocytes 
after simultaneous MG132/SB treatment seems to have a synergistic effect with HDAC inhibitor 
since both of them leads to a decrease of hypophosphorylated pRb (Figure-3.10). It has been 
previously reported that the cellular level of Rb is regulated by ubiquitin-dependent proteolysis 
in HPV-positive cervical cancer (Wang et al., 2001) and in other tumor cells, such as human lung 
cancer (Uchida et al., 2005). 
The detailed mechanism of how pRb is degraded by proteasome system is not completely 
understood. It has been suggested that E7 may function as an adaptor between pRb and the 
proteasome without prior ubiquitination. Initial studies revealed an interaction between E7 and 
the S4 ATPase subunit of the 19S regulatory complex of the 26S proteasome. Furthermore it is 
known that E7 binds pRb and S4 through independent domains, it is possible that an E7/Rb/S4 
quaternary complex forms an intermediate step leading to the proteolytic degradation of pRb 
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(Berezustkaya et al., 1997). Recent reports indicate that the HPV16E7 associates with the 
enzymatically active Cullin-2 ubiquitin ligase complex and that the HPV16E7/pRb complex 
contains Cullin-2 (Huh et al., 2007). Therefore analyses of the association between Cullin-2 and 
HPV18E7/pRb complex and its role in enhanced degradation of pRb upon HDAC inhibition will 
be the objective of further studies.  
Nevertheless, the initial ubiquitination analyses of pRb upon HDAC inhibition remains 
unsuccessful (data not shown). However, recent data show that pRb can be degraded via the 
proteasome in an ubiquitin independent manner (Kalejta et al., 2003; Sdek et al., 2005). Thus 
several studies demonstrate the involvement of the 20S proteasome in pRb degradation 
(Orlowski et al., 2003). Interestingly, Tanahashi et al., (2000) demonstrated that the estimated 
concentration of the 20S proteasome in HeLa cells was approximately twice as high as the 
amount of the 26S or 20S-11S-REG complexes. Thus it would be interesting to analyse whether 
the 20S proteasome plays a role in the trimeric complex consisting of Rb-26S / 20S-E7 by 
HDAC inhibition. The fate of the trimeric complexes of pRb/E7/26S or 20S upon HDAC 
inhibition is urgently necessary be analysed.  
In addition, the contribution of other pRb destabilization proteins to the degradation process 
following HDAC inhibition needs to be clarified. For example, the cellular oncoprotein gankyrin 
contains also the LXCXE Rb-binding motif and target pRb for its degradation in either ubiquitin-
dependent or ubiquitin-independent proteasome pathways (Higashitsuji et al., 2000 and 2005; 
Dawson et al., 2006; Nakamura et al., 2007). The exact molecular mechanisms, however, remain 
elusive. 
Since pRb binds many nuclear proteins including MDM2 (Uchida et al., 2005) and BRCA1 
(Hashizume et al, 2001), which have ubiquitin ligase activities, these interaction partners could 
also be investigated in the future. Interestingly, a recent report of Sdek et al., showed that MDM2 
binds the C8 subunit of 20S proteasome and promotes Rb-C8 interaction, leading to a 
proteasome-dependent ubiquitin-independent degradation of Rb both in vivo and in vitro. This 
finding further indicates that ubiquitination is not always a prerequisite for the proteasomal 
degradation of pRb (2005). 
Recently, it was found that E7 promotes C-terminal cleavage of pRb, (a 95 kDa fragment (pRb(1-
810)), by calcium-activated cysteine protease calpain and that this cleavage is required before E7 
can promote proteasomal degradation of pRb (Darnell et al., 2007). Considering this recent data 
and the knowledge that MG132 can also block the calpains, experiments to clarify the role of the 
calpains in E7 mediated pRb degradation by HDAC inhibition need to be performed.  
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4.5 HDACi mediated cell cycle arrest and induction of apoptosis in HPV positive cells 
 
4.5.1 HDACi mediated cell cycle arrest 
It has previously been shown that HDAC inhibitors can cause cell-cycle arrest in G1 and /or G2 
phase and apoptosis in cultured cells (Marks et al., 2001). From a large number of studies it is 
known that this is often associated with the p53-independent induction of CDKN1A (a p21 
promoter) (El-Deiry et al., 1995; Gui t al., 2004; Varshochi et al., 2005). HDACi mediated cell 
cycle arrest was concomitant with p21 upregulation in HeLa cells (Figure-3.14 and 3.15) as 
previously shown by Finzer et al., (2001). 
The induction of the CDKNA1 might not be solely responsible for the G1 arrest observed, as 
HDACi-mediated repression of cyclin D and cyclin A genes are likely to contribute to the loss of 
CDK2 and CDK4 kinase activities and hypophosphorylation of pRb which is sequentially 
phosphorylated during entry into S phase by cyclin D/CDK4 and CDK6 complexes and Cyclin 
E/CDK2 complexes (Kim et al., 1999; Qiu et al., 2000; Sandor et al., 2000; Finzer et al., 2001). 
Surprisingly, transactivation of cyclin E is not associated with CDK2 activity, but likely due to 
the concomitant increase of p21 levels and subsequent the loss of the pRb repression on cyclin E 
promoter (Sambucetti et al., 1999; Sandor et al., 2000; Kim et al., 1999).  
The cell cycle arrest in the presence of E7 seems to be quite contradictory, as it is known that 
viral proteins E6 and E7 promote cell cycle progression. From our previous data we know that 
HPVE7 is not responsible for the observed cell cycle arrest, as it was shown that the HPV 
transcription was deregulated but the posttranslational level of HPV was not affected by HDAC 
inhibition (Finzer et al., 2002). Moreover studies with C33-A clearly demonstrate that the 
presence of HPV is not a prerequisite for HDACi induced cell cycle arrest in cervical cancer 
cells (Figure-3.15 C). Here we observed a cell cycle arrest in G2/M- phase. Several studies 
reported that G2/M arrest, which is activated by G2-phase checkpoint, is a much rarer event than 
HDACi induced G1 arrest (Qiu et al., 2000; Burgess et al., 2001). Nevertheless this demonstrates 
that HDACi induced cell cycle arrest (G1 and/ or G2 phase) is not dependent on the HPV 
content. Moreover HDACi induced cell cycle arrest has been shown to be irreversible and 
resembles replicative senescence (Richon et al., 2000; Archer et al., 1998). Indeed, a study 
demonstrates that the function of E6 and E7 can be circumvented during the senescence (Chen et 
al., 1993). Interestingly modification of E7 by TLCK can abolish the HDAC inhibitor induced 
cell cycle arrest independent of modifying the E7 protein. The observed dose dependent 
downregulation of p21 confirms the accumulation of cells in S-phase (Figure-3.16 A and B). 
TLCK mediated p21 downregulation implies that TLCK can reverse the SB mediated effect 
independent of the E7 modification. Indeed as a general serine protease inhibitor the effects of 
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the TLCK can not be limited only to the E7 protein modifications, since several serine/threonine 
kinases are involved in regulating cell proliferation and cell death (see discussion 4.5.2). 
Experiments addressing the direct role of the E7 in HDACi mediated cell cycle arrest, needs to 
be analysed with TLCK co-treatment in E6 and E7-immortalised keratinocytes. 
 
4.5.2 HDACi mediated apoptosis 
The therapeutic potential of HDACi stems from their capacity to selectively induce apoptosis in 
tumor cells compared with normal cells. In agreement with previous studies (Drummond et al., 
2005; Kelly et al., 2005), treatment with HDAC inhibitor causes an increased apoptotic cell 
population after longer treatment of HeLa cells (Figure-3.17 A and B).  
One explanation for this observation could be the direct induction of the p21 gene at chromatin 
level. It is well known, that at the restriction point of G1-phase, a decision is made either G1 
arrest and/or apoptosis (King and Cidlowski, 1998). Furthermore many regulators of the cell 
cycle play key roles in apoptosis regulation (Craig et al., 1997; Katayose et al., 1997). 
Nevertheless, the observed apoptosis cannot be explained by the upregulation of the p21 since 
several studies reported that p21 upregulation induced by HDACi, reduces the HDACi mediated 
cytotoxicity (Burgess et al., 2001). The observation of strong degradation of pRb, while E7 
protein did not considerably change upon HDACi, strongly indicates that the loss of pRb is the 
cause of apoptosis. Depending on the cell system and the external stimulus, pRb can be also 
cleaved by activated caspase-3 during apoptosis, meaning that pRb degradation is a consequence 
of the apoptotic stimulus (Boutillier et al., 2000; Chau et al., 2002). But previous data by our 
group demonstrated that the degradation of pRb upon HDACi in HeLa cells was independent of 
caspase cleavage (Finzer et al., 2004). 
Conversely, several studies showed that loss of pRb can sensitize the cells to apoptosis (Du and 
Pogoriler, 2006) as demonstrated in various tissues of Rb-/- mice. In fact, pRb acts not only as a 
transcriptional corepressor that controls cell cycle progression (Zhang and Dean, 2001), its 
absence in pRb-deficient cells is associated with increased rates of apoptosis (reviewed by Chau 
and Wang 2003). One of the several models which try to explain the apoptotic phenotype of RB-
null cells propose that suppression of apoptosis is a primary function of pRb, independent of its 
antiproliferative activity (Chau and Wang 2003). Since the inactivation of pRb can stimulate 
proliferation and apoptosis, and the pRb/E2F complex regulates the expression of S phase and 
apoptotic genes (Nevins et al., 2001; Muller et al., 2001), it is possible that Rb/E2F promoter 
complexes could be differentially regulated in response to mitogenic and apoptotic signals. The 
promoter–specific regulation of Rb/E2F transcription complex at the promoters of S-phase genes 
is regulated through pRb phosphorylation, whereas at the promoters of apoptotic genes, the main 
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regulatory step is the degradation of pRb. This model would predict that a fraction of the 
pRb/E2F repression complexes are stable and functional in proliferating cells (Chau and Wang, 
2003).  
Loss of pRb leads to accumulation of free E2F and transactivating genes and induction of the 
intrinsic apoptotic pathway (Qin et al., 1994; Almasan et al., 1995; Lieman 2005).  
The degradation of the pRb during HDACi mediated apoptosis obviously requires the presence 
of the E7 oncoprotein (Finzer et al., 2001 and 2004). It is known that E7 inherently controls the 
half-life of pRb and enforces its intracellular degradation upon HDACi which in turn diminishes 
the anti-apoptotic activity of pRb. Notably, reports from a previous study have shown that E7 
can also interact with E2F-1 in a pRb-independent manner and thereby increasing the E2F-1 
proapoptotic activity (Hwang et al., 2002). This observation was confirmed by immortalised 
keratinocytes in which only the E7 immortalised keratinocytes were strongly apoptotic while the 
E6 keratinocytes were not (Stöppler et al., 1998; Finzer et al., 2001). Also a report from Iglesias 
et al., (1998) confirms the presence of E7 for E2F-1 mediated apoptosis upon sensitisation of the 
keratinocytes.  
Interestingly, HPV negative cervical carcinoma cells C33-A were not sensitive to HDACi 
induced cell death (Figure-3.17 C). Therefore apoptosis analyses of the HPV-negative cells C33-
A confirmed that the cells were not sensitive to HDAC inhibitor treatment. Moreover, PARP 
cleavage of the HPV positive cells clearly contributes to the role of HPV in apoptosis upon 
HDACi treatment (Figure-3.5.6).   
These data indicate an essential role of HPV presence in apoptosis in cervical carcinoma cells 
induced by HDAC inhibitor SB and TSA. Moreover loss of pRb upon HDACi provides some 
evidence of their anticancer activity which is accounted for transcription-independent effect 
(Cohen et al., 2004; Subramanian 2005).   
A large number of independent studies strongly support a role for the mitochondrial apoptotic 
pathway in HDACi-mediated tumor cell death. These data show that overexpression of BCL2 or 
BCL-XL, both blocked the intrinsic apoptotic pathway, inhibit apoptosis mediated by diverse 
HDAC inhibitors irrespective of cell type (Ruefli et al., 2001; Peart et al., 2003; Mitsiades et al., 
2003; Zhao et al., 2005).  
Since HDAC inhibitors stabilize the E2F protein by acetylation (Caron et al., 2005) it is 
conceivable that the anti-proliferative effect could occur by inducing the E2F/p14ARF/p53 
pathway. Thus E2F-1 triggers the activation of p14ARF, which in turn leads to stabilization of p53 
by inhibiting its E3 ligase MDM-2 (Zhang et al., 1998; Pomerantz et al., 1998). However this 
possibility can be excluded, because the protein level of p53 remained unaffected up to 32 h in 
the presence of HDAC inhibitors and elevated p21CIP1/WAF-1 (Finzer et al., 2004). Nevertheless 
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p53 can be also acetylated by HDAC inhibitors (Bolden 2006), which would contribute for its 
stabilisation and strengthen its potential as an inducer of apoptosis. Ev3en though the levels of 
p53 can be reduced by E6 oncoprotein inherently (Münger and Howley 2002; zur Hausen, 2002), 
the residual p53 levels could still participate in apoptosis. Hence, experiments where cells 
transfected with p53 specific siRNAs showed that the apoptotic rate was not influenced upon SB 
treatment (Finzer et al., 2004).  
Since the p53-dependent mechanism can be ruled out in HDAC inhibitor induced apoptosis, 
other candidate molecules were investigated which can be also induced by E2F transcription 
factor. Previous reports considering the microarray analyses on HeLa cells where E2F activity 
was induced by HDAC inhibitor SB, did not show any induction of the potential target genes like 
p14ARF, Apaf-1 (Moroni et al., 2001) and Bcl-2 (Gomez-Manzano et al., 2001) (Finzer et al., 
unpublished data). Nevertheless this supports the notion that the range of induced E2F genes is 
not activated in all cell systems (Stanelle et al., 2002). 
Phillips and Vousden (2001) reported an E2F1 induced apoptosis via the p53 homolog p73 
(Irwin et al., 2000). While p53 is posttranslationally stabilized by MDM2 and p14ARF, the p73 
activation by E2F-1 occurs via binding to E2F-1 responsive site within the p73 TA promoter, 
which finally acts exclusively on transcription. We observed an upregulation of p73 at 
transcriptional level as demonstrated in Figure-3.18 A (HeLa) and in Figure-19 B (E7 
keratinocytes respectively). This correlates with the previous observation of apoptotic analyses 
(Figure-3.17 A, B and Finzer et al., 2001). 
The slight upregulation of p73 in E6 keratinocytes (Figure-3.19 D, E) can be explained by the 
fact that p73 is not a target for E6 oncoprotein, unlike p53 (Melino et al., 2002), which indicates 
that p53 and p73 are differentially recognized by viral proteins. Also the reduced level of E2F in 
E6 keratinocytes upon HDACi confirms that this induction of p73 involves other transcriptional 
regulation than via E2F. Actually it is shown that p73 can be induced by other transcription 
factors such as c-Myc (Zaika et al., 2001). However the interplay between c-Myc and p73 is still 
controversial (Watanabe et al., 2002).  
Interestingly, co-treatment with TLCK did not only influence HDAC inhibitor mediated 
enhanced pRb degradation in the presence of E7 oncoprotein but also reduced transcription of 
the apoptotic p73 in HPV positive HeLa cells and in E7 immortalised keratinocytes (see Figure-
3.19 A, B). This would explain the recovery of the pRb protein and thereby reduced sensitivity to 
apoptosis. The dose-dependent decrease of the p73 transcription following TLCK and SB co-
treatment, significantly confirms the reduction of the G1 arrest in HeLa cells (see Figure-3.16). 
The strong accumulation in S phase supports that SB mediated G1 arrest can be reversed (see 
3.16 B).  
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As a general serine protease inhibitor, TLCK mediated effects cannot be restricted to 
modifications of E7 protein. It has been shown that TLCK and TPCK (also a serine protease 
inhibitor) can inhibit a wide range of general cellular functions including chemotaxis (Barna et 
al., 1995), gene expression (Griscavage et al., 1995), aortic relaxation (Rodriguez et al., 1996), 
and apoptosis (Yoshida et al., 1996; Mitsui et al., 2001; Okada et al., 2004). 
As previously mentioned several serine/threonine kinases are involved in regulating the cell 
proliferation and cell death. Kuninaka et al., (2007) demonstrated that the serine protease 
Omi/HtrA2 targets WARTS kinases to control the cell proliferation. WARTS are serine/threonin 
proteases which interact with the mitochondrial serine protease Omi/HtrA2 (Srinivasula et al., 
2003; Salvesen and Duckett, 2002) and induce their protease activity. Omi/HtrA2 was previously 
identified to be released into the cytosol by apoptotic stimuli and induced cell death through its 
own serine protease activity, attenuating the activity of IAPs (inhibitor of apoptosis proteins) 
(Suzuki et al., 2001; Hegde et al., 2002; Martins et al., 2002; Verhagen et al., 2002).  
Moreover, Yang et al., (2007) reported that serine/threonine kinases Akt1 and Akt2 (Franke et 
al., 1995; Burgering et al., 1995; Cross et al.,1995) phosphorylate the mitochondria-released 
HtrA2/Omi on serine 212 in vivo and in vitro, which results in attenuation of its serine protease 
activity and pro-apoptotic function. Interestingly, mitochondrial release of the Omi/HtrA2 was 
previously demonstrated by the group of Garcia–Morales (2005) following apoptotic stimulus 
with HDAC inhibitors. Further studies should address the apoptotic fate of the cells upon TLCK 
and SB co-treatment in E6 and E7- immortalised keratinocytes. Furthermore it would be 
interesting to evaluate the role of p73 in HPV negative cervical carcinoma cells and how these 
cells would be affected upon co-treatment with TLCK. Also measurement of the transmembrane 
potential by cytochrome C release upon SB (Finzer et al., 2004) and TLCK co-treatment would 
help to understand the role of the mitochondrial pathway in the used cell system.   
The splice variant, ΔNp73 transcripts of p73 gene which lacks the transactivation domain 
(exon1-3) function as an antiapoptotic protein (Yang et al., 2002). ΔNp73 is a dominant negative 
inhibitor of the TAp73 which was shown to be upregulated after longer treatment with SB (24h) 
and therefore accounting for reduced expression of TAp73 (Finzer et al., 2004). Determining the 
expression level of this antiapoptotic splice variant in E6 immortalised keratinocytes would be 
interesting, since it is known that these cells did not undergo apoptosis by HDAC inhibition 
(Finzer et al., 2001). 
p73 induced apoptosis involves the induction of PUMA (a BH3 only protein), which in turn 
promotes Bax mitochondrial translocation and cytochrome C release in a time dependent manner 
(Melino et al., 2004). However, Bax protein levels did not correlate with the kinetics of apoptosis 
(Ramadan et al., 2005). Whereas p73-induced and PUMA mediated mitochondrial translocation 
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of Bax is kinetically compatible with the induction of cell death (Ramadan et al., 2005). This 
might explain why Bax expression was not observed in response to SB treatment (Finzer et al 
unpublished data). p73 is localized in the nucleus, and remains nuclear during the induction of 
apoptosis. This indicates that the effect of p73 on Bax is indirect. Thus a direct interaction of p73 
with PUMA would be interesting to demonstrate by immunprecipitation upon SB treatment in 
our cellular systems. Nevertheless the localisation of the p73 in nucleus might be also examined 
upon SB.  
 
Conclusion and Future Perspective: 
In this present study it was shown that the presence of HPV E7 is a prerequisite for HDAC 
inhibitor SB and TSA mediated pRb degradation. This degradation mainly occurs by a 
proteasome dependent pathway. Nevertheless, possible co-factors such as E3 ligases, which 
could be involved in enhanced degradation of pRb or other mechanism contributing to its 
degradation, should be determined. Moreover these data confirm that the presence of HPV E7 
sensitizes the cells for SB mediated apoptosis which can be reversed by posttranslational 
modification of the HPV E7. 
Furthermore co-treatment of SB with TLCK demonstrates that the HDAC inhibition mediated 
degradation of pRb can be rescued. This results in an increase of the repressive function of pRb 
on E2F transcription factor which subsequently reduces the transcription of the apoptotic gene 
p73. Down-regulation of p21 by TLCK further interferes with SB mediated cell cycle arrest. 
Finally the HDAC inhibitor mediated apoptosis can be inhibited by TLCK. Subsequently this 
study bears new future aspects in understanding the role of serine proteases during HDAC 
inhibition.  
HDACi show a promise as single agent anticancer drugs in HPV-induced carcinogenesis: they 
first force HPV-positive cells to arrest the cell cycle, and subsequently trigger the intrinsic 
apoptosis by targeting the pRb/E2F/p73 pathway without impairing oncogene suppression. 
Given the range of molecular and biological responses that these agents can elicit and minimal 
toxicity to normal cells, the combination with other agents such as with proteasome inhibitor 
MG132, could prove to be their most useful application (Bolden et al., 2006). 
 
Figure-4.1 illustrates the main themes of this work. 
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Figure-4.1: HDAC inhibitor induced cell cycle and apoptosis is influenced by TLCK. 
HDAC inhibition of HPV positive HeLa cells induces the expression of the cyclin–dependent kinase inhibitor 
p21 resulting in G1 arrest. Prolonged treatment with SB triggers the induction of apoptosis only in E7 positive 
cells (HeLa and E7 immortalised keratinocytes). Enhanced degradation of pRb occurs only in E7 containing 
cells upon HDAC inhibition. Loss of pRb leads to a “free E2F” which induces the transcription of the pro-
apoptotic genes p73. TLCK treatment influencing the SB mediated effect: first restoring the pRb level and 
reducing the expression of the p21. Cell cycle arrest is inhibited by entry in the S phases. Secondly the re-
establishment of the hypophosphorylated pRb acts again as a repressor protein and reduced the expression of 
the p73. 
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